47 results on '"Ioannis Ntalas"'
Search Results
2. Handling Post-COVID-19 Sequelae: A Need for Multispecialty Approach
- Author
-
George Makrydakis, Lamprini Markaki, Emmanouil-Dimitrios Manikas, Ioannis Ntalas, and Nikolaos Spernovasilis
- Subjects
post-COVID-19 ,sequelae ,infectious disease specialist ,multispecialty management ,primary care ,pandemic ,Public aspects of medicine ,RA1-1270 - Published
- 2022
- Full Text
- View/download PDF
3. Emerging role of cardiac computed tomography in heart failure
- Author
-
Waqar Aziz, Simon Claridge, Ioannis Ntalas, Justin Gould, Adelaide deVecchi, Orod Razeghi, Daniel Toth, Peter Mountney, Rebecca Preston, Christopher A. Rinaldi, Reza Razavi, Steven Niederer, and Ronak Rajani
- Subjects
Heart failure ,Cardiac computed tomography ,Bioengineering ,CT fusion ,Cardiomyopathy ,CT dyssynchrony ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Despite medical advancements, the prognosis of patients with heart failure remains poor. While echocardiography and cardiac magnetic resonance imaging remain at the forefront of diagnosing and monitoring patients with heart failure, cardiac computed tomography (CT) has largely been considered to have a limited role. With the advancements in scanner design, technology, and computer processing power, cardiac CT is now emerging as a valuable adjunct to clinicians managing patients with heart failure. In the current manuscript, we review the current applications of cardiac CT to patients with heart failure and also the emerging areas of research where its clinical utility is likely to extend into the realm of treatment, procedural planning, and advanced heart failure therapy implementation.
- Published
- 2019
- Full Text
- View/download PDF
4. Clinical value of dark-blood late gadolinium enhancement cardiovascular magnetic resonance without additional magnetization preparation
- Author
-
Robert J. Holtackers, Caroline M. Van De Heyning, Muhummad Sohaib Nazir, Imran Rashid, Ioannis Ntalas, Haseeb Rahman, René M. Botnar, and Amedeo Chiribiri
- Subjects
Late enhancement ,Late gadolinium enhancement ,LGE ,Dark-blood ,Myocardial scar ,Subendocardial scar ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background For two decades, bright-blood late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) has been considered the reference standard for the non-invasive assessment of myocardial viability. While bright-blood LGE can clearly distinguish areas of myocardial infarction from viable myocardium, it often suffers from poor scar-to-blood contrast, making subendocardial scar difficult to detect. Recently, we proposed a novel dark-blood LGE approach that increases scar-to-blood contrast and thereby improves subendocardial scar conspicuity. In the present study we sought to assess the clinical value of this novel approach in a large patient cohort with various non-congenital ischemic and non-ischemic cardiomyopathies on both 1.5 T and 3 T CMR scanners of different vendors. Methods Three hundred consecutive patients referred for clinical CMR were randomly assigned to a 1.5 T or 3 T scanner. An entire short-axis stack and multiple long-axis views were acquired using conventional phase sensitive inversion recovery (PSIR) LGE with TI set to null myocardium (bright-blood) and proposed PSIR LGE with TI set to null blood (dark-blood), in a randomized order. The bright-blood LGE and dark-blood LGE images were separated, anonymized, and interpreted in a random order at different time points by one of five independent observers. Each case was analyzed for the type of scar, per-segment transmurality, papillary muscle enhancement, overall image quality, observer confidence, and presence of right ventricular scar and intraventricular thrombus. Results Dark-blood LGE detected significantly more cases with ischemic scar compared to conventional bright-blood LGE (97 vs 89, p = 0.008), on both 1.5 T and 3 T, and led to a significantly increased total scar burden (3.3 ± 2.4 vs 3.0 ± 2.3 standard AHA segments, p = 0.015). Overall image quality significantly improved using dark-blood LGE compared to bright-blood LGE (81.3% vs 74.0% of all segments were of highest diagnostic quality, p = 0.006). Furthermore, dark-blood LGE led to significantly higher observer confidence (confident in 84.2% vs 78.4%, p = 0.033). Conclusions The improved detection of ischemic scar makes the proposed dark-blood LGE method a valuable diagnostic tool in the non-invasive assessment of myocardial scar. The applicability in routine clinical practice is further strengthened, as the present approach, in contrast to other recently proposed dark- and black-blood LGE techniques, is readily available without the need for scanner adjustments, extensive optimizations, or additional training.
- Published
- 2019
- Full Text
- View/download PDF
5. Importance of operator training and rest perfusion on the diagnostic accuracy of stress perfusion cardiovascular magnetic resonance
- Author
-
Adriana D. M. Villa, Laura Corsinovi, Ioannis Ntalas, Xenios Milidonis, Cian Scannell, Gabriella Di Giovine, Nicholas Child, Catarina Ferreira, Muhummad Sohaib Nazir, Julia Karady, Esmeralda Eshja, Viola De Francesco, Nuno Bettencourt, Andreas Schuster, Tevfik F. Ismail, Reza Razavi, and Amedeo Chiribiri
- Subjects
Cardiovascular magnetic resonance ,Stress perfusion imaging ,Coronary artery disease ,Quantitative assessment ,Myocardial ischemia ,Diagnostic accuracy ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background Clinical evaluation of stress perfusion cardiovascular magnetic resonance (CMR) is currently based on visual assessment and has shown high diagnostic accuracy in previous clinical trials, when performed by expert readers or core laboratories. However, these results may not be generalizable to clinical practice, particularly when less experienced readers are concerned. Other factors, such as the level of training, the extent of ischemia, and image quality could affect the diagnostic accuracy. Moreover, the role of rest images has not been clarified. The aim of this study was to assess the diagnostic accuracy of visual assessment for operators with different levels of training and the additional value of rest perfusion imaging, and to compare visual assessment and automated quantitative analysis in the assessment of coronary artery disease (CAD). Methods We evaluated 53 patients with known or suspected CAD referred for stress-perfusion CMR. Nine operators (equally divided in 3 levels of competency) blindly reviewed each case twice with a 2-week interval, in a randomised order, with and without rest images. Semi-automated Fermi deconvolution was used for quantitative analysis and estimation of myocardial perfusion reserve as the ratio of stress to rest perfusion estimates. Results Level-3 operators correctly identified significant CAD in 83.6% of the cases. This percentage dropped to 65.7% for Level-2 operators and to 55.7% for Level-1 operators (p
- Published
- 2018
- Full Text
- View/download PDF
6. Giant left atrium: Adaptive or maladaptive?
- Author
-
Ioannis Ntalas, Steven Niederer, Waqar Aziz, John B. Chambers, and Ronak Rajani
- Subjects
Rheumatic valve disease ,Atrial dilatation ,Echocardiography ,Cardiac computed tomography ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Published
- 2019
- Full Text
- View/download PDF
7. Effect of active vitamin-D on left ventricular mass index: Results of a randomized controlled trial in type 2 diabetes and chronic kidney disease
- Author
-
Luigi Gnudi, Nikolaos Fountoulakis, Angeliki Panagiotou, Antonella Corcillo, Giuseppe Maltese, Maria Flaquer Rife, Ioannis Ntalas, Russell Franks, Amedeo Chiribiri, Salma Ayis, and Janaka Karalliedde
- Subjects
Cardiology and Cardiovascular Medicine - Published
- 2023
8. Simultaneous Dual Coronary Fistulas
- Author
-
Ioannis Ntalas, John B. Chambers, Júlia Karády, and Ronak Rajani
- Subjects
Systolic Murmurs ,Echocardiography ,Computed Tomography Angiography ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Full Text
- View/download PDF
9. A Machine-Learning Framework to Identify Distinct Phenotypes of Aortic Stenosis Severity
- Author
-
Partho P. Sengupta, Sirish Shrestha, Nobuyuki Kagiyama, Yasmin Hamirani, Hemant Kulkarni, Naveena Yanamala, Rong Bing, Calvin W.L. Chin, Tania A. Pawade, David Messika-Zeitoun, Lionel Tastet, Mylène Shen, David E. Newby, Marie-Annick Clavel, Phillippe Pibarot, Marc R. Dweck, Éric Larose, Ezequiel Guzzetti, Mathieu Bernier, Jonathan Beaudoin, Marie Arsenault, Nancy Côté, Russell Everett, William S.A. Jenkins, Christophe Tribouilloy, Julien Dreyfus, Tiffany Mathieu, Cedric Renard, Mesut Gun, Laurent Macron, Jacob W. Sechrist, Joan M. Lacomis, Virginia Nguyen, Laura Galian Gay, Hug Cuéllar Calabria, Ioannis Ntalas, Bernard Prendergast, Ronak Rajani, Arturo Evangelista, and João L. Cavalcante
- Subjects
macromolecular substances ,030204 cardiovascular system & hematology ,Machine learning ,computer.software_genre ,Severity of Illness Index ,Asymptomatic ,030218 nuclear medicine & medical imaging ,Machine Learning ,03 medical and health sciences ,0302 clinical medicine ,Aortic valve replacement ,Predictive Value of Tests ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Decompensation ,Adverse effect ,Heart Valve Prosthesis Implantation ,medicine.diagnostic_test ,business.industry ,Magnetic resonance imaging ,Aortic Valve Stenosis ,medicine.disease ,Confidence interval ,3. Good health ,Stenosis ,Phenotype ,Aortic Valve ,Cohort ,Artificial intelligence ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,computer - Abstract
Objectives The authors explored the development and validation of machine-learning models for augmenting the echocardiographic grading of aortic stenosis (AS) severity. Background In AS, symptoms and adverse events develop secondarily to valvular obstruction and left ventricular decompensation. The current echocardiographic grading of AS severity focuses on the valve and is limited by diagnostic uncertainty. Methods Using echocardiography (ECHO) measurements (ECHO cohort, n = 1,052), we performed patient similarity analysis to derive high-severity and low-severity phenogroups of AS. We subsequently developed a supervised machine-learning classifier and validated its performance with independent markers of disease severity obtained using computed tomography (CT) (CT cohort, n = 752) and cardiovascular magnetic resonance (CMR) imaging (CMR cohort, n = 160). The classifier’s prognostic value was further validated using clinical outcomes (aortic valve replacement [AVR] and death) observed in the ECHO and CMR cohorts. Results In 1,964 patients from the 3 multi-institutional cohorts, 1,346 (68%) subjects had either nonsevere or discordant AS severity. Machine learning identified 1,117 (57%) patients as having high-severity and 847 (43%) as having low-severity AS. High-severity patients in CT and CMR cohorts had higher valve calcium scores and left ventricular mass and fibrosis, respectively than the low-severity group. In the ECHO cohort, progression to AVR and progression to death in patients who did not receive AVR was faster in the high-severity group. Compared with the conventional classification of disease severity, machine-learning–based severity classification improved discrimination (integrated discrimination improvement: 0.07; 95% confidence interval: 0.02 to 0.12) and reclassification (net reclassification improvement: 0.17; 95% confidence interval: 0.11 to 0.23) for the outcome of AVR at 5 years. For both ECHO and CMR cohorts, we observed prognostic value of the machine-learning classifications for subgroups with asymptomatic, nonsevere or discordant AS. Conclusions Machine learning can integrate ECHO measurements to augment the classification of disease severity in most patients with AS, with major potential to optimize the timing of AVR.
- Published
- 2021
10. Worldwide Disparities in Recovery of Cardiac Testing 1 Year Into COVID-19
- Author
-
Andrew J. Einstein, Cole Hirschfeld, Michelle C. Williams, Joao V. Vitola, Nathan Better, Todd C. Villines, Rodrigo Cerci, Leslee J. Shaw, Andrew D. Choi, Sharmila Dorbala, Ganesan Karthikeyan, Bin Lu, Valentin Sinitsyn, Alexey A. Ansheles, Takashi Kudo, Chiara Bucciarelli-Ducci, Bjarne Linde Nørgaard, Pál Maurovich-Horvat, Roxana Campisi, Elisa Milan, Lizette Louw, Adel H. Allam, Mona Bhatia, Lorenzo Sewanan, Eli Malkovskiy, Yosef Cohen, Michael Randazzo, Jagat Narula, Olga Morozova, Thomas N.B. Pascual, Yaroslav Pynda, Maurizio Dondi, Diana Paez, Gerd Hinterleitner, Yao Lu, Zhuoran Xu, Cole B. Hirschfeld, Ikenna Erinne, Mrinali Shetty, Andrew Choi, Juan Lopez-Mattei, Purvi Parwani, Artan Goda, Ervina Shirka, Salah Bouyoucef, Lydia Chelghoum, Farouk Mansouri, Abdelkader Medjahedi, Qais Naili, Mokhtar Ridouh, Diego Alasia, Lucia Alberghina, Natalia Aramayo, Diego Buchara, Franco Gabriel Busso, Jose Javier Bustos Rivadero, Jorge Camilletti, Hugo Campanelli, Ricardo Belisario Castro, Mariana Daicz, Horacio del Riego, Laura Dragonetti, Diego Echazarreta, Juan Erriest, Fernando Faccio, Adolfo Facello, Hugo Gallegos, Ricardo Geronazzo, Horacio Glait, Victor Hasbani, Victor Jäger, Julio Manuel Lewkowicz, Jose Lotti, Neiva Maciel, Osvaldo Masoli, Edgardo Mastrovito, Maria Medus, Maria Fernanda Merani, Susana Molteni, Marcos Montecinos, Gustavo Parisi, Claudio Pereyra Sueldo, Diego Perez de Arenaza, Luis Quintana, Alejandro Radzinschi, Marcela Redruello, Marina Rodríguez, Horacio Rojas, Arturo Romero Acuña, Daniel Schere, Sonia Traverso, Gustavo Vazquez, Susana Zeffiro, Mari Sakanyan, Scott Beuzeville, Raef Boktor, Michael Crowley, D'Arne Downie, Girish Dwivedi, Barry Elison, Omar Farouque, Kim Jasper, Subodh Joshi, Joseph Lee, Kenneth Lee, Elaine Lui, Peter Mcconachie, Joanne Meaker, Dee Nandurkar, Johanne Neill, Edward O'Rourke, Patricia O'Sullivan, George Pandos, Manuja Premaratne, David Prior, Natalie Rutherford, Connor Saunders, Kim Taubman, Andrew Tauro, Andrew Taylor, James Theuerle, Paul Thomas, Jonathan Tow, Anthony Upton, Shankar Vamadevan, Victor Wayne, Eva Alina Wegner, David Wong, John Younger, Dietrich Beitzke, Gudrun Feuchtner, Oliver Sommer, Konrad Weiss, Natallia Maroz-Vadalazhskaya, Uladzimir Tserakhau, Filip Homans, Caroline M. Van De Heyning, Raúl Araujo, Valentina Soldat-Stankovic, Sinisa Stankovic, Augusto Almeida, Carlos Anselmi, Guilherme S.A. Azevedo, Marcio Sommer Bittencourt, Diego Bromfman Pianta, Estevan Cabeda, Lara Carreira, Igor Coelho, Fernando de Amorim Fernandes, Andrea de Lorenzo, Roberta Delgado, Fernanda Erthal, Fabio Fernandes, Juliano Fernandes, Thiago Ferreira de Souza, Murilo Foppa, Wilson Furlan Matos Alves, Cibele Gontijo, Ilan Gottlieb, Gabriel Grossman, Maria Helena Albernaz Siqueira, Cesar Higa Nomura, Katia Hiromoto Koga, Ronaldo Lima, Rafael Lopes, Hugo Humberto Marçal Filho, Paulo Masiero, Luiz Mastrocola, Maria Eduarda Menezes de Siqueira, Claudio Mesquita, Danilo Naves, Filipe Penna, Ibraim Pinto, Thércio Rocha, Juliana Leal Rocha, Alfredo Rodrigues, Leila Salioni, Adelina Sanches, Marcelo Santos, Leonardo Sara Da Silva, Paulo Schvartzman, Cristina Sebastião Matushita, Tiago Senra, Marcelo Silva, Carlos Eduardo Soares, Bernardo Spiro, Carlos Eduardo Suaide Silva, Rafael Torres, Guilherme Urpia Monte, Andrea Vilela, Alexandre Volney Villa, Joao Vitola, Themissa Voss, Roberto Waltrick, Marcello Zapparoli, Hamid Naseer, Marina Garcheva-Tsacheva, Tiémégna Florence Ouattara, Sarameth Thou, Soley Varoeun, Gad Abikhzer, Rob Beanlands, Michael Chetrit, Dominique Dabreo, Carole Dennie, Matthias Friedrich, Mohmmed Nassoh Hafez, Kate Hanneman, Robert Miller, Anastasia Oikonomou, Idan Roifman, Gary Small, Vikas Tandon, Adwait Trivedi, James White, Katherine Zukotynski, Rita Alay, Carmen Concha, Teresa Massardo, Pedro Abad, Kelly Anzola, Harold Arturo, Luis Benitez, Alberto Cadena, Carlos Caicedo Zamudio, Antonio Calderón, Claudia T. Gutierrez Villamil, Claudia Jaimes, Juan L. Londono, Nelson Lopez, Sonia Merlano-Gaitan, Ramon Murgieitio-Cabrera, Manuel Valencia, Damiana Vergel, Alejandro Zuluaga Santamaria, Felix Solis, Tonci Batinic, Maja Franceschi, Maja Hrabak Paar, Marina Prpic, Cuba: Juan Felipe Batista, Lazaro Omar Cabrera, Amalia Peix, Yamilé Peña, Luis Manuel Rochela Vázquez, Ioannis Ntalas, Milan Kaminek, Vladimir Kincl, Otto Lang, Jawdat Abdulla, Morten Bøttcher, Martin Busk, Uka Geisler, Lars C. Gormsen, Nicolaj Hansson, Søren Hess, Jens Hove, Lars Thorbjoern Jensen, Magnus T. Jensen, Kristian Hay Kragholm, Bjarne L. Nørgaard, Kristian Øvrehus, Jan Rasmussen, Niels Peter Rønnow Sand, Hanne Sondergaard, Tomas Zaremba, Herwin Speckter, Nelson Amores, Mayra Sanchez Velez, Taghreed Abd Alrahman, Sherif Abd Elsamad, Alia Abdelfattah, Adel Allam, Sameh Elkaffas, Mona Hassan, Elshaymaa Hussein, Ahmed Ibrahim, Ahmed Kandeel, Mohamed Mandour Ali, Mahmoud Shaaban, Camila Flores, Verónica Vanesa Gómez Leiva, Anita Liiver, Martti Larikka, Valtteri Uusitalo, Denis Agostini, Clothilde Berger, Matthieu Dietz, Fabien Hyafil, Mickaël Ohana, Kevin Prigent, Hamza Regaieg, Laure Sarda-Mantel, Darach O. H-Ici, Harold Ayetey, George Angelidis, Christina Fragkaki, Chrysoula Fragkiadaki, Panagiotis Georgoulias, Maria Koutelou, Elena Kyrozi, Niki Lama, Vassilis Prassopoulos, Michael Spartalis, Theodora Zaglavara, Carla Gonzalez, Goleat Gutierrez, Alejandro Maldonado, Yassine Martinez, Attila Kovács, Bálint Szilveszter, Nilesh Banthia, Vivek Bhat, Partha Choudhury, Vijay Sai Chowdekar, Johann Christopher, Tushar Garg, Naresh Kumar Goyal, Ripen Kumar Gupta, Abhishek Gupta, Julie Hephzibah, Shashank Jain, Jesu Krupa, Parveen Kumar, Sukriti Kumar, Arati Lalchandani, Animesh Mishra, Vivaswan Dutt Mishra, Parul Mohan, Ahmad Ozair, Shivani Pandey, Ramanathapuram Parameswaran, Chetan Patel, Tapan Patel, Shivani Patel, Leena Robinson Vimala, Dr Pradosh Kumar Sarangi, Shantanu Sengupta, Arvind Sethi, Amit Sharma, Awadhesh Kumar Sharma, Punit Sharma, Apurva Shrigiriwar, Santosh Singh, Harpreet Singh, Ashwani Sood, Atul Verma, Ajay Vyas, Erwin Affandi Soeriadi, Edison Bun, Febby Hutomo, Hilman Syawaluddin, Ryan Yudistiro, Amjed Albadr, Majid Assadi, Farshad Emami, Alireza Emami-Ardekani, Saeed Farzanehfar, Ramezan Jafari, Reyhaneh Manafi-Farid, Maryam Tajik, Yoav Arnson, Shmuel Fuchs, Ronen Goldkorn, John Kennedy, Marina Leitman, Aryeh Shalev, Wanda Acampa, Domenico Albano, Pierpaolo Alongi, Gaspare Arnone, Roberta Assante, Anna Baritussio, Matteo Bauckneht, Francesco Bianco, Rachele Bonfiglioli, Francesco Bovenzi, Isabella Bruno, Andrea Bruno, Elena Busnardo, Elena Califaretti, Roberta Casoni, Vittorio Censullo, Franca Chierichetti, Marcello Chiocchi, Corrado Cittanti, Alberto Clemente, Alberto Cuocolo, Maria Luisa De Rimini, Giuseppe De Vincentis, Veronica Della Tommasina, Santo Dellegrottaglie, Paola Anna Erba, Laura Evangelista, Lara Faggi, Evelina Faragasso, Luigia Florimonte, Viviana Frantellizzi, Marco Gatti, Angela Gaudiano, Fabrizia Gelardi, Alberto Gerali, Alessia Gimelli, Marco Guglielmo, Lucia Leccisotti, Riccardo Liga, Carlo Liguori, Giampiero Longo, Margherita Maffione, Claudio Marcassa, Giovanni Matassa, Donato Mele, Luca Mircoli, Andrea Paccagnella, Sara Pacella, Federica Padovano, Dario Pellegrini, Valeria Pergola, Luca Pugliese, Natale Quartuccio, Lucia Rampin, Fabrizio Ricci, Giuseppe Rubini, Vincenzo Russo, Gianmario Sambuceti, Alessandra Scatteia, Roberto Sciagrà, Gianluca Spidalieri, Antonella Stefanelli, Carlo Tedeschi, Guido Ventroni, Dainia Baugh, Ernest Madu, Tadao Aikawa, Hiroshi Asano, Shinichiro Fujimoto, Koichiro Fujise, Yoshimitsu Fukushima, Kae Fukuyama, Yasutaka Ichikawa, Reiko Ideguchi, Nobuo Iguchi, Masamichi Imai, Hayato Ishimura, Satoshi Isobe, Kimiteru Ito, Yu Izawa, Toshiaki Kadokami, Tokuo Kasai, Takao Kato, Takashi Kawamoto, Shigeru Kiryu, Shinichiro Kumita, Osamu Manabe, Hirotaka Maruno, Naoya Matsumoto, Masao Miyagawa, Masao Moroi, Shigeki Nagamachi, Kenichi Nakajima, Ryo Nakazato, Mamoru Nanasato, Masanao Naya, Takashi Norikane, Yasutoshi Ohta, Yoichi Otomi, Hideki Otsuka, Noriko Oyama-Manabe, Masaki Saito, Masayoshi Sarai, Junichi Sato, Daisuke Sato, Shinya Shiraishi, Kentaro Takanami, Kazuya Takehana, Yasuyo Taniguchi, Hiroki Teragawa, Nobuo Tomizawa, Kyoko Umeji, Yasushi Wakabayashi, Shinichiro Yamada, Shinya Yamazaki, Tatsuya Yoneyama, Mohammad Rawashdeh, Tairkhan Dautov, Khalid Makhdomi, Mostafa Abass, Masoud Garashi, Qaisar Siraj, Marika Kalnina, Mohamad Haidar, Renata Komiagiene, Giedre Kviecinskiene, Donatas Vajauskas, Noor Khairiah A. Karim, Mady Doucoure, Luise Reichmuth, Anthony Samuel, Mohamed Lemine Dieng, Ambedhkar Shantaram Naojee, Estrella Aguilera Hernandez, Cesar Rene Alducin Tellez, Erick Alexánderson-Rosas, Erika Barragan, Manuel Cabada, Daniel Calderón, Isabel Carvajal-Juarez, José Esparza, Manlio Gerardo Gama-Moreno, Virginia Garcia Quinto, Nelsy Coromoto Gonzalez, Mary Carmen Herrera-Zarza, Aloha Meave, Jesus Gregorio Medina Verdugo, Gabriela Melendez, Rafael Humberto Morales Murguia, Carlos Salvador Navarro Quiroz, Mario Ornelas, Andres Preciado-Anaya, Oscar Ulises Preciado-Gutiérrez, Adriana Puente, Aristóteles Ramírez Salazar, Sandra Graciela Rosales Uvera, Sandra Rosales-Uvera, Jose Antonio Serna Macias, Lilia Sierra-Galan, Lilia M. Sierra-Galan, Juan Carlos Tirado Alderete, Enrique Vallejo, Marc Faraggi, Erdenechimeg Sereegotov, Nouzha Ben Rais, Nadia Ismaili Alaoui, Thiri Kyiphyu, Su Thet Oo, Soe Myat Win, Htin Zar, Ram Ghimire, Madhu Neupane, Andor Glaudemans, Riemer Slart, Derk Verschure, Berry Allen, John Edmond, Clare Mckenzie, Stuart Tie, Niels Van Pelt, Kirsten Worthington, Calum Young, Idrissa Adamou Soli, Shehu Kana, Uchenna Onubogu, Mahmoud Sani, Anders Tjellaug Bråten, Arve Jørgensen, Hanne-Elin Vassbotn, Humoud Al Dhuhli, Zabah Jawa, Naima Tag, Shazia Fatima, Muhammad Babar Imran, Muhammad Numair Younis, Mohammad Saadullah, Yariela Herrera Malo, Dora Lenturut-Katal, Manuel Castillo, José Ortellado, Afroza Akhter, F. Aaysha Cader, Raihan Hussain, Saidur Rahman Khan, Tapati Mandal, Faria Nasreen, Yunqiang An, Dianbo Cao, Lianggeng Gong, Yang Hou, Chongfu Jia, Tao Li, Caiying Li, Hui Liu, Wenya Liu, Jinkang Liu, Ming-Yen Ng, Heshui Shi, Chunxiang Tang, Ximing Wang, Zhaoqian Wang, Yining Wang, Jiang Wu, Yan Yi, Li Yuan, Tong Zhang, Longjiang Zhang, Edith Chavez, Carlos Cruz, Christian Llontop, Rosanna Morales, Paz Abrihan, Asela Bustos-Barroso, Michele Duldulao-Ogbac, Christopher Eduarte, Jerry Obaldo, Alvin Quinon, Belinda San Juan, Carlo Joe San Juan, Marie Rhiamar Sauler-Gomez, Mila Uy, Magdalena Kostkiewicz, Jolanta Kunikowska, Anna Teresinska, Tomasz Urbanik, Nuno Bettencourt, Ricardo Fontes-Carvalho, Cristina Gavina, Lino Gonçalves, Filipe Macedo, Nuno Moreno, Carla Sousa, Ana Teresa Timoteo, Maria João Vidigal, Mahmoud Al Heidous, Subramaniyan Ramanathan, Samer Arnous, Said Aytani, Angela Byrne, Tadhg Gleeson, David Kerins, Julie O'Brien, Ji-In Bang, Henry Bom, Miju Cheon, Gi Jeong Cheon, Sang-Geon Cho, Chae Moon Hong, Yong Hyu Jeong, Won Jun Kang, Yeon-Koo Kang, Ji-Young Kim, So Won Oh, Young So, Ho-Chun Song, Kyoung Sook Won, Soo Woong Yoo, Irena Mitevska, Marija Vavlukis, Barbara Gužic Salobir, Monika Štalc, Theodora Benedek, Marian Pop, Claudiu Stan, Alexey Ansheles, Olga Dariy, Nina Gagarina, Irina Itskovich, Anatoliy Karalkin, Alexander Kokov, Gulya Marina, Ekaterina Migunova, Viktor Pospelov, Daria Ryzhkova, Guzaliya Sayfullina, Vladimir Sergienko, Irina Shurupova, Margarita Vakhromeeva, Nailia Valiullina, Konstantin Zavadovsky, Kirill Zhuravlev, Rami Abazid, Turki Al Garni, Mirvat Alasnag, Ahmed Aljizeeri, Hamid Amer, Ahmad Amro, Hesham Hamdy, Osama Smettei, Dragana Sobic Saranovic, Marina Vlajkovic, Felix Keng, Jason See, Zuzana Berecova, Jana Polakova Mistinova, Osayande Evbuomwan, Nerisha Govender, Jonathan Hack, Bawinile Hadebe, Khanyisile Hlongwa, Mitchell Kaplan, Hoosen Lakhi, Katarina Milos, Moshe Modiselle, Stuart More, Ntanganedzeni Muambadzi, Leonie Scholtz, Manuel Barreiro-Perez, Isabel Blanco, Jordi Broncano, Alicia Camarero, Irene Casáns-Tormo, Javier De Haro, Albert Flotats, Elia García, Ceferino Gutierrez Mendiguchia, Amelia Jimenez-Heffernan, Ruben Leta, Javier Lopez Diaz, Luis Lumbreras Vega, Ana Manovel-Sánchez, Amparo Martinez Monzonis, Bianca Patrut, Virginia Pubul, Ricardo Ruano Perez, Nahla Zeidan, Damayanthi Nanayakkara, Ahmed Suliman, Henrik Engblom, Mustafa Murtadha, Ellen Ostenfeld, Magnus Simonsson, Hatem Alkadhi, Ronny Ralf Buechel, Peter Burger, Christoph Gräni, Christel Kamani, Nadine Kawel-Böhm, Bernd Klaeser, Robert Manka, John Prior, Tawika Kaewchur, Benjapa Khiewvan, Arpakorn Kositwattanarerk, Sirianong Namwongprom, Tanyaluck Thientunyakit, Haluk Burcak Sayman, Mahmut Yüksel, Mugisha Julius Sebikali, Emmy Okello, Pavlo Korol, Iryna Noverko, Maryna Satyr, Tahir Ahmad, Khaled Alfakih, Ivo Andrade, Susan Buckingham, Anda Bularga, John-Paul Carpenter, Graham Cole, David Cusack, Sarojini David, Patrick Davis, Timothy Fairbairn, Arjun Ghosh, Prasad Guntur Ramkumar, Mark Hamilton, Faisal Haque, Benjamin Hudson, Annette Johnstone, V.J. Karthikeyan, Mike Kay, Mohammad Ali Khan, Jamie Kitt, Chen Sheng Low, Elisa Mcalindon, David Mccreavy, Brian Morrissey, Manish Motwani, Dilip Na, Edward Nicol, Dilip Patel, Jonathan Rodrigues, Chris Rofe, Rebecca Schofield, Thomas Semple, Azeem Sheikh, Apurva Sinha, Deepak Subedi, William Topping, Katherine Tweed, Stephen Richard Underwood, Jonathan Weir-Mccall, Hamed Zuhairy, Taimur Abbasi, Shady Abohashem, Sandra Abramson, Mouaz Al-Mallah, Mohan Ashok Kumar, Mallory Balmer-Swain, Daniel Berman, Adam Bernheim, Sabha Bhatti, Robert Biederman, Erik Bieging, Scott Bingham, Stephen Bloom, Sean Blue, Andressa Borges, Kelley Branch, Paco Bravo, Sujatha Buddhe, Matthew Budoff, Renée Bullock-Palmer, Michael Cahill, Candace Candela, Jane Cao, Saurav Chatterjee, Yiannis Chatzizisis, Nita Ray Chaudhuri, Michael Cheezum, Anjali Chelliah, Tiffany Chen, Marcus Chen, Lu Chen, Aalap Chokshi, Jina Chung, Sorin Danciu, William DeSisto, Michael Dilorenzo, Rami Doukky, William Duvall, Maros Ferencik, Cameron Foster, Anthon Fuisz, Michael Gannon, David German, Myron Gerson, Jeffrey Geske, Fadi Hage, Agha Haider, Sofia Haider, Yasmin Hamirani, Karen Hassen, Robert Hendel, Jacqueline Henkel, Stephen Horgan, Mark Hyun, Rajesh Janardhanan, Scott Jerome, Dinesh Kalra, David Kassop, Mona Kinkhabwala, George Kinzfogl, Bernard Koch, Lynne Koweek, Joseph Krepp, Younghoon Kwon, Jay Layer, John Lesser, Steve Leung, Bernadette Lisske, Kathleen Magurany, Jeremy Markowitz, Brenda Mccullough, Azita Moalemi, Chanan Moffitt, Juan Montanez, Warren Moore, Shamil Morayati, Mahmud Mossa-Basha, Zorana Mrsic, Venkatesh Murthy, Prashant Nagpal, Katarina Nelson, Prabhjot Nijjar, Rupal O’Quinn, Edward Passen, Toral Patel, Pravin Patil, Amit Pursnani, Nancy Quachang, Mark Rabbat, Pragya Ranjan, Patricia Rodriguez Lozano, Mary Schemmer, Rebecca Seifried, Nishant Shah, Amee Shah, Sujata Shanbhag, Gaurav Sharma, Robert Skotnicki, Michael Sobczak, Prem Soman, Vincent Sorrell, Monvadi Srichai, Jim Streeter, Leah Strickland, Suliman Suliman, Naghmeh Tebyanian, Dustin Thomas, Randall Thompson, Seth Uretsky, Srikanth Vallurupalli, Marian Vandyck-Acquah, Vikas Verma, Todd Villines, Joseph Weinstein, David Wolinsky, Karolina Zareba, Michael Zgaljardic, Mario Beretta, Rodolfo Ferrando, Miguel Kapitan, Fernando Mut, Omoa Djuraev, Gulnora Rozikhodjaeva, Luisa Vera, Binh Duong Duc, Xuan Canh Nguyen, Phuoc Minh Hiep Nguyen, Translational Immunology Groningen (TRIGR), Cardiovascular Centre (CVC), Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Molecular Pharmacology, Drug Design, Einstein, A, Hirschfeld, C, Williams, M, Vitola, J, Better, N, Villines, T, Cerci, R, Shaw, L, Choi, A, Dorbala, S, Karthikeyan, G, Lu, B, Sinitsyn, V, Ansheles, A, Kudo, T, Bucciarelli-Ducci, C, Norgaard, B, Maurovich-Horvat, P, Campisi, R, Milan, E, Louw, L, Allam, A, Bhatia, M, Sewanan, L, Malkovskiy, E, Cohen, Y, Randazzo, M, Narula, J, Morozova, O, Pascual, T, Pynda, Y, Dondi, M, Paez, D, Hinterleitner, G, Lu, Y, Xu, Z, Erinne, I, Shetty, M, Lopez-Mattei, J, Parwani, P, Goda, A, Shirka, E, Bouyoucef, S, Chelghoum, L, Mansouri, F, Medjahedi, A, Naili, Q, Ridouh, M, Alasia, D, Alberghina, L, Aramayo, N, Buchara, D, Busso, F, Bustos Rivadero, J, Camilletti, J, Campanelli, H, Castro, R, Daicz, M, del Riego, H, Dragonetti, L, Echazarreta, D, Erriest, J, Faccio, F, Facello, A, Gallegos, H, Geronazzo, R, Glait, H, Hasbani, V, Jager, V, Lewkowicz, J, Lotti, J, Maciel, N, Masoli, O, Mastrovito, E, Medus, M, Merani, M, Molteni, S, Montecinos, M, Parisi, G, Sueldo, C, Perez de Arenaza, D, Quintana, L, Radzinschi, A, Redruello, M, Rodriguez, M, Rojas, H, Acuna, A, Schere, D, Traverso, S, Vazquez, G, Zeffiro, S, Sakanyan, M, Beuzeville, S, Boktor, R, Crowley, M, Downie, D, Dwivedi, G, Elison, B, Farouque, O, Jasper, K, Joshi, S, Lee, J, Lee, K, Lui, E, Mcconachie, P, Meaker, J, Nandurkar, D, Neill, J, O'Rourke, E, O'Sullivan, P, Pandos, G, Premaratne, M, Prior, D, Rutherford, N, Saunders, C, Taubman, K, Tauro, A, Taylor, A, Theuerle, J, Thomas, P, Tow, J, Upton, A, Vamadevan, S, Wayne, V, Wegner, E, Wong, D, Younger, J, Beitzke, D, Feuchtner, G, Sommer, O, Weiss, K, Maroz-Vadalazhskaya, N, Tserakhau, U, Homans, F, Van De Heyning, C, Araujo, R, Soldat-Stankovic, V, Stankovic, S, Almeida, A, Anselmi, C, Azevedo, G, Bittencourt, M, Pianta, D, Cabeda, E, Carreira, L, Coelho, I, de Amorim Fernandes, F, de Lorenzo, A, Delgado, R, Erthal, F, Fernandes, F, Fernandes, J, Ferreira de Souza, T, Foppa, M, Matos Alves, W, Gontijo, C, Gottlieb, I, Grossman, G, Albernaz Siqueira, M, Nomura, C, Koga, K, Lima, R, Lopes, R, Marcal Filho, H, Masiero, P, Mastrocola, L, Menezes de Siqueira, M, Mesquita, C, Naves, D, Penna, F, Pinto, I, Rocha, T, Rocha, J, Rodrigues, A, Salioni, L, Sanches, A, Santos, M, Da Silva, L, Schvartzman, P, Matushita, C, Senra, T, Silva, M, Soares, C, Spiro, B, Suaide Silva, C, Torres, R, Monte, G, Vilela, A, Villa, A, Voss, T, Waltrick, R, Zapparoli, M, Naseer, H, Garcheva-Tsacheva, M, Ouattara, T, Thou, S, Varoeun, S, Abikhzer, G, Beanlands, R, Chetrit, M, Dabreo, D, Dennie, C, Friedrich, M, Hafez, M, Hanneman, K, Miller, R, Oikonomou, A, Roifman, I, Small, G, Tandon, V, Trivedi, A, White, J, Zukotynski, K, Alay, R, Concha, C, Massardo, T, Abad, P, Anzola, K, Arturo, H, Benitez, L, Cadena, A, Zamudio, C, Calderon, A, Gutierrez Villamil, C, Jaimes, C, Londono, J, Lopez, N, Merlano-Gaitan, S, Murgieitio-Cabrera, R, Valencia, M, Vergel, D, Santamaria, A, Solis, F, Batinic, T, Franceschi, M, Paar, M, Prpic, M, Felipe Batista, C, Cabrera, L, Peix, A, Pena, Y, Rochela Vazquez, L, Ntalas, I, Kaminek, M, Kincl, V, Lang, O, Abdulla, J, Bottcher, M, Busk, M, Geisler, U, Gormsen, L, Hansson, N, Hess, S, Hove, J, Jensen, L, Jensen, M, Kragholm, K, Ovrehus, K, Rasmussen, J, Ronnow Sand, N, Sondergaard, H, Zaremba, T, Speckter, H, Amores, N, Velez, M, Alrahman, T, Elsamad, S, Abdelfattah, A, Elkaffas, S, Hassan, M, Hussein, E, Ibrahim, A, Kandeel, A, Ali, M, Shaaban, M, Flores, C, Gomez Leiva, V, Liiver, A, Larikka, M, Uusitalo, V, Agostini, D, Berger, C, Dietz, M, Hyafil, F, Ohana, M, Prigent, K, Regaieg, H, Sarda-Mantel, L, H-Ici, D, Ayetey, H, Angelidis, G, Fragkaki, C, Fragkiadaki, C, Georgoulias, P, Koutelou, M, Kyrozi, E, Lama, N, Prassopoulos, V, Spartalis, M, Zaglavara, T, Gonzalez, C, Gutierrez, G, Maldonado, A, Martinez, Y, Kovacs, A, Szilveszter, B, Banthia, N, Bhat, V, Choudhury, P, Chowdekar, V, Christopher, J, Garg, T, Goyal, N, Gupta, R, Gupta, A, Hephzibah, J, Jain, S, Krupa, J, Kumar, P, Kumar, S, Lalchandani, A, Mishra, A, Mishra, V, Mohan, P, Ozair, A, Pandey, S, Parameswaran, R, Patel, C, Patel, T, Patel, S, Vimala, L, Kumar Sarangi, D, Sengupta, S, Sethi, A, Sharma, A, Sharma, P, Shrigiriwar, A, Singh, S, Singh, H, Sood, A, Verma, A, Vyas, A, Soeriadi, E, Bun, E, Hutomo, F, Syawaluddin, H, Yudistiro, R, Albadr, A, Assadi, M, Emami, F, Emami-Ardekani, A, Farzanehfar, S, Jafari, R, Manafi-Farid, R, Tajik, M, Arnson, Y, Fuchs, S, Goldkorn, R, Kennedy, J, Leitman, M, Shalev, A, Acampa, W, Albano, D, Alongi, P, Arnone, G, Assante, R, Baritussio, A, Bauckneht, M, Bianco, F, Bonfiglioli, R, Bovenzi, F, Bruno, I, Bruno, A, Busnardo, E, Califaretti, E, Casoni, R, Censullo, V, Chierichetti, F, Chiocchi, M, Cittanti, C, Clemente, A, Cuocolo, A, De Rimini, M, De Vincentis, G, Della Tommasina, V, Dellegrottaglie, S, Erba, P, Evangelista, L, Faggi, L, Faragasso, E, Florimonte, L, Frantellizzi, V, Gatti, M, Gaudiano, A, Gelardi, F, Gerali, A, Gimelli, A, Guglielmo, M, Leccisotti, L, Liga, R, Liguori, C, Longo, G, Maffione, M, Marcassa, C, Matassa, G, Mele, D, Mircoli, L, Paccagnella, A, Pacella, S, Padovano, F, Pellegrini, D, Pergola, V, Pugliese, L, Quartuccio, N, Rampin, L, Ricci, F, Rubini, G, Russo, V, Sambuceti, G, Scatteia, A, Sciagra, R, Spidalieri, G, Stefanelli, A, Tedeschi, C, Ventroni, G, Baugh, D, Madu, E, Aikawa, T, Asano, H, Fujimoto, S, Fujise, K, Fukushima, Y, Fukuyama, K, Ichikawa, Y, Ideguchi, R, Iguchi, N, Imai, M, Ishimura, H, Isobe, S, Ito, K, Izawa, Y, Kadokami, T, Kasai, T, Kato, T, Kawamoto, T, Kiryu, S, Kumita, S, Manabe, O, Maruno, H, Matsumoto, N, Miyagawa, M, Moroi, M, Nagamachi, S, Nakajima, K, Nakazato, R, Nanasato, M, Naya, M, Norikane, T, Ohta, Y, Otomi, Y, Otsuka, H, Oyama-Manabe, N, Saito, M, Sarai, M, Sato, J, Sato, D, Shiraishi, S, Takanami, K, Takehana, K, Taniguchi, Y, Teragawa, H, Tomizawa, N, Umeji, K, Wakabayashi, Y, Yamada, S, Yamazaki, S, Yoneyama, T, Rawashdeh, M, Dautov, T, Makhdomi, K, Abass, M, Garashi, M, Siraj, Q, Kalnina, M, Haidar, M, Komiagiene, R, Kviecinskiene, G, Vajauskas, D, Karim, N, Doucoure, M, Reichmuth, L, Samuel, A, Dieng, M, Naojee, A, Hernandez, E, Alducin Tellez, C, Alexanderson-Rosas, E, Barragan, E, Cabada, M, Calderon, D, Carvajal-Juarez, I, Esparza, J, Gama-Moreno, M, Quinto, V, Gonzalez, N, Herrera-Zarza, M, Meave, A, Medina Verdugo, J, Melendez, G, Morales Murguia, R, Navarro Quiroz, C, Ornelas, M, Preciado-Anaya, A, Preciado-Gutierrez, O, Puente, A, Salazar, A, Rosales Uvera, S, Rosales-Uvera, S, Serna Macias, J, Sierra-Galan, L, Tirado Alderete, J, Vallejo, E, Faraggi, M, Sereegotov, E, Ben Rais, N, Alaoui, N, Kyiphyu, T, Oo, S, Win, S, Zar, H, Ghimire, R, Neupane, M, Glaudemans, A, Slart, R, Verschure, D, Allen, B, Edmond, J, Mckenzie, C, Tie, S, Van Pelt, N, Worthington, K, Young, C, Soli, I, Kana, S, Onubogu, U, Sani, M, Braten, A, Jorgensen, A, Vassbotn, H, Al Dhuhli, H, Jawa, Z, Tag, N, Fatima, S, Imran, M, Younis, M, Saadullah, M, Malo, Y, Lenturut-Katal, D, Castillo, M, Ortellado, J, Akhter, A, Cader, F, Hussain, R, Khan, S, Mandal, T, Nasreen, F, An, Y, Cao, D, Gong, L, Hou, Y, Jia, C, Li, T, Li, C, Liu, H, Liu, W, Liu, J, Ng, M, Shi, H, Tang, C, Wang, X, Wang, Z, Wang, Y, Wu, J, Yi, Y, Yuan, L, Zhang, T, Zhang, L, Chavez, E, Cruz, C, Llontop, C, Morales, R, Abrihan, P, Bustos-Barroso, A, Duldulao-Ogbac, M, Eduarte, C, Obaldo, J, Quinon, A, San Juan, B, San Juan, C, Sauler-Gomez, M, Uy, M, Kostkiewicz, M, Kunikowska, J, Teresinska, A, Urbanik, T, Bettencourt, N, Fontes-Carvalho, R, Gavina, C, Goncalves, L, Macedo, F, Moreno, N, Sousa, C, Timoteo, A, Vidigal, M, Al Heidous, M, Ramanathan, S, Arnous, S, Aytani, S, Byrne, A, Gleeson, T, Kerins, D, O'Brien, J, Bang, J, Bom, H, Cheon, M, Cheon, G, Cho, S, Hong, C, Jeong, Y, Kang, W, Kang, Y, Kim, J, Oh, S, So, Y, Song, H, Won, K, Yoo, S, Mitevska, I, Vavlukis, M, Salobir, B, Stalc, M, Benedek, T, Pop, M, Stan, C, Dariy, O, Gagarina, N, Itskovich, I, Karalkin, A, Kokov, A, Marina, G, Migunova, E, Pospelov, V, Ryzhkova, D, Sayfullina, G, Sergienko, V, Shurupova, I, Vakhromeeva, M, Valiullina, N, Zavadovsky, K, Zhuravlev, K, Abazid, R, Al Garni, T, Alasnag, M, Aljizeeri, A, Amer, H, Amro, A, Hamdy, H, Smettei, O, Saranovic, D, Vlajkovic, M, Keng, F, See, J, Berecova, Z, Mistinova, J, Evbuomwan, O, Govender, N, Hack, J, Hadebe, B, Hlongwa, K, Kaplan, M, Lakhi, H, Milos, K, Modiselle, M, More, S, Muambadzi, N, Scholtz, L, Barreiro-Perez, M, Blanco, I, Broncano, J, Camarero, A, Casans-Tormo, I, De Haro, J, Flotats, A, Garcia, E, Mendiguchia, C, Jimenez-Heffernan, A, Leta, R, Diaz, J, Vega, L, Manovel-Sanchez, A, Monzonis, A, Patrut, B, Pubul, V, Perez, R, Zeidan, N, Nanayakkara, D, Suliman, A, Engblom, H, Murtadha, M, Ostenfeld, E, Simonsson, M, Alkadhi, H, Buechel, R, Burger, P, Grani, C, Kamani, C, Kawel-Bohm, N, Klaeser, B, Manka, R, Prior, J, Kaewchur, T, Khiewvan, B, Kositwattanarerk, A, Namwongprom, S, Thientunyakit, T, Sayman, H, Yuksel, M, Sebikali, M, Okello, E, Korol, P, Noverko, I, Satyr, M, Ahmad, T, Alfakih, K, Andrade, I, Buckingham, S, Bularga, A, Carpenter, J, Cole, G, Cusack, D, David, S, Davis, P, Fairbairn, T, Ghosh, A, Ramkumar, P, Hamilton, M, Haque, F, Hudson, B, Johnstone, A, Karthikeyan, V, Kay, M, Khan, M, Kitt, J, Low, C, Mcalindon, E, Mccreavy, D, Morrissey, B, Motwani, M, Na, D, Nicol, E, Patel, D, Rodrigues, J, Rofe, C, Schofield, R, Semple, T, Sheikh, A, Sinha, A, Subedi, D, Topping, W, Tweed, K, Underwood, S, Weir-Mccall, J, Zuhairy, H, Abbasi, T, Abohashem, S, Abramson, S, Al-Mallah, M, Kumar, M, Balmer-Swain, M, Berman, D, Bernheim, A, Bhatti, S, Biederman, R, Bieging, E, Bingham, S, Bloom, S, Blue, S, Borges, A, Branch, K, Bravo, P, Buddhe, S, Budoff, M, Bullock-Palmer, R, Cahill, M, Candela, C, Cao, J, Chatterjee, S, Chatzizisis, Y, Chaudhuri, N, Cheezum, M, Chelliah, A, Chen, T, Chen, M, Chen, L, Chokshi, A, Chung, J, Danciu, S, Desisto, W, Dilorenzo, M, Doukky, R, Duvall, W, Ferencik, M, Foster, C, Fuisz, A, Gannon, M, German, D, Gerson, M, Geske, J, Hage, F, Haider, A, Haider, S, Hamirani, Y, Hassen, K, Hendel, R, Henkel, J, Horgan, S, Hyun, M, Janardhanan, R, Jerome, S, Kalra, D, Kassop, D, Kinkhabwala, M, Kinzfogl, G, Koch, B, Koweek, L, Krepp, J, Kwon, Y, Layer, J, Lesser, J, Leung, S, Lisske, B, Magurany, K, Markowitz, J, Mccullough, B, Moalemi, A, Moffitt, C, Montanez, J, Moore, W, Morayati, S, Mossa-Basha, M, Mrsic, Z, Murthy, V, Nagpal, P, Nelson, K, Nijjar, P, O'Quinn, R, Passen, E, Patil, P, Pursnani, A, Quachang, N, Rabbat, M, Ranjan, P, Lozano, P, Schemmer, M, Seifried, R, Shah, N, Shah, A, Shanbhag, S, Sharma, G, Skotnicki, R, Sobczak, M, Soman, P, Sorrell, V, Srichai, M, Streeter, J, Strickland, L, Suliman, S, Tebyanian, N, Thomas, D, Thompson, R, Uretsky, S, Vallurupalli, S, Vandyck-Acquah, M, Verma, V, Weinstein, J, Wolinsky, D, Zareba, K, Zgaljardic, M, Beretta, M, Ferrando, R, Kapitan, M, Mut, F, Djuraev, O, Rozikhodjaeva, G, Vera, L, Duc, B, Nguyen, X, Hiep Nguyen, P, Einstein, Andrew J, Hirschfeld, Cole, Williams, Michelle C, Vitola, Joao V, Better, Nathan, Villines, Todd C, Cerci, Rodrigo, Shaw, Leslee J, Choi, Andrew D, Dorbala, Sharmila, Karthikeyan, Ganesan, Lu, Bin, Sinitsyn, Valentin, Ansheles, Alexey A, Kudo, Takashi, Bucciarelli-Ducci, Chiara, Nørgaard, Bjarne Linde, Maurovich-Horvat, Pál, Campisi, Roxana, Milan, Elisa, Louw, Lizette, Allam, Adel H, Bhatia, Mona, Sewanan, Lorenzo, Malkovskiy, Eli, Cohen, Yosef, Randazzo, Michael, Narula, Jagat, Morozova, Olga, Pascual, Thomas N B, Pynda, Yaroslav, Dondi, Maurizio, Paez, Diana, and Cuocolo, Alberto
- Subjects
cardiac testing ,Health Personnel ,delivery of health care ,coronavirus ,COVID-19 ,global health ,610 Medicine & health ,cardiovascular disease ,health personnel ,humans ,pandemics ,surveys and questionnaires ,coronaviru ,Surveys and Questionnaires ,Humans ,Cardiology and Cardiovascular Medicine ,Delivery of Health Care ,Pandemics ,COVID-19/epidemiology - Abstract
BACKGROUND: The extent to which health care systems have adapted to the COVID-19 pandemic to provide necessary cardiac diagnostic services is unknown.OBJECTIVES: The aim of this study was to determine the impact of the pandemic on cardiac testing practices, volumes and types of diagnostic services, and perceived psychological stress to health care providers worldwide.METHODS: The International Atomic Energy Agency conducted a worldwide survey assessing alterations from baseline in cardiovascular diagnostic care at the pandemic's onset and 1 year later. Multivariable regression was used to determine factors associated with procedure volume recovery.RESULTS: Surveys were submitted from 669 centers in 107 countries. Worldwide reduction in cardiac procedure volumes of 64% from March 2019 to April 2020 recovered by April 2021 in high- and upper middle-income countries (recovery rates of 108% and 99%) but remained depressed in lower middle- and low-income countries (46% and 30% recovery). Although stress testing was used 12% less frequently in 2021 than in 2019, coronary computed tomographic angiography was used 14% more, a trend also seen for other advanced cardiac imaging modalities (positron emission tomography and magnetic resonance; 22%-25% increases). Pandemic-related psychological stress was estimated to have affected nearly 40% of staff, impacting patient care at 78% of sites. In multivariable regression, only lower-income status and physicians' psychological stress were significant in predicting recovery of cardiac testing.CONCLUSIONS: Cardiac diagnostic testing has yet to recover to prepandemic levels in lower-income countries. Worldwide, the decrease in standard stress testing is offset by greater use of advanced cardiac imaging modalities. Pandemic-related psychological stress among providers is widespread and associated with poor recovery of cardiac testing.
- Published
- 2022
11. Συγκριτική μελέτη της αντιαιμοπεταλιακής δράσης διαφορετικών αλάτων της κλοπιδογρέλης σε ασθενείς με καρδιαγγειακή νόσο
- Author
-
Ioannis Ntalas
- Abstract
Η κλοπιδογρέλη είναι ένα ευρέως χρησιμοποιούμενο αντιαιμοπεταλιακό φάρμακο για τη δευτερογενή πρόληψη αθηροθρομβωτικών επεισοδίων, σε συνδυασμό με ασπιρίνη ή ως μονοθεραπεία. Το κλινικό όφελος της κλοιδογρέλης έχει καθιερωθεί με μια πληθώρα μεγάλων κλινικών μελετών, καθώς και στην παγκόσμια κλινική πρακτική. Όλη αυτή η γνώση και η εμπειρία έχουν ληφθεί χρησιμοποιώντας το πρωτότυπο σκεύασμα της όξινης θειϊκής κλοπιδογρέλης (CHS-Plavix® / Iscover®). Μετά τη λήξη των φαρμακευτικών διπλωμάτων ευρεσιτεχνίας της τον Μάιο του 2012, η κλοπιδογρέλη έχει καταστεί γενόσημηκαι έτσι διάφορα εμπορικά σκευάσματα έχουν αναπτυχθεί και εγκριθεί για χρήση σε όλο τον κόσμο, συμπεριλαμβανομένης της Ευρώπης και των ΗΠΑ,για τη δευτερογενή πρόληψη των αθηροθρομβωτικών επεισοδίων. Σε αυτά περιλαμβάνονται η κλοπιδογρέλη βάσης, η κλοπδογρέλη resinate, ηυδροχλωρική κλοπιδογρέλη και η βεσυλική κλοπιδογρέλη (CB). Κατά την ανάπτυξη μιας νέας γενόσημης μορφής, είναι σημαντικό να συμμορφώνονταιμε τη διαδικασία παρασκευής και να χρησιμοποιούνται τα ίδια έκδοχα όπως και στο αρχικό άλας, προκειμένου να ελαχιστοποιηθούν τα προβλήματα σταθερότητας. Συγκεκριμένα, κατά τη διάρκεια της φάσης ανάπτυξης μιας από του στόματος στερεής μορφής, αρκετές φυσικοχημικές δοκιμές προ κα ιμετά διαμόρφωσης του σκευάσματος διεξάγονται προκειμένου να επιτευχθεί ένα υψηλής ποιότητας γενόσημο προϊόν που είναι ισάξιο με το αρχικό πρωτότυπο σκεύασμα από την άποψη της αποτελεσματικότητας και της ασφάλειας . Κατά συνέπεια, ένα γενόσημο προϊόν πρέπει να παρουσιάζει ένα προφίλ διάλυσης in vitro, παρόμοιο ή επικαλυπτόμενο εκείνου του αρχικού προϊόντος, προκειμένου να εξασφαλισθεί ένα πετυχημένο προφίλ βιοϊσοδυναμίας του προϊόντος. Ωστόσο, σύμφωνα με το βιοφαρμακευτικό σύστημα ταξινόμησης, η κλοπιδογρέλη είναι ένα προϊόν Class II και η in vitroδιάλυση δεν αρκεί για να αποδείξει ότι είναι ισάξια με το πρωτότυπο σκεύασμα. Έτσι, τα γενόσημα δισκία κλοπιδογρέλης θα πρέπει ναυποβάλλονται σε μελέτη βιοϊσοδυναμίας σε σύγκριση με το πρωτότυπο σκεύασμα. Επιπλέον, είναι κρίσιμης σημασίας να αποδειχθεί ότι αυτά ταπαρασκευάσματα έχουν παρόμοια φαρμακοδυναμική δραστικότητα στηναναστολή της δραστικότητας των αιμοπεταλίων και επίσης είναι κλινικά βιοϊσοδύναμα με το αρχικό άλας από την άποψη της αποτελεσματικότητας και της ασφάλειας. Σε αυτό το πλαίσιο, θα πρέπει να τονιστεί ότι σε αντίθεση με άλλα γενικά καρδιαγγειακά φάρμακα, όπως οι στατίνες ή τααντιυπερτασικά, για τα οποία μικρές διαφορές στην βιολογική αποτελεσματικότητά τους θα ήταν απίθανο να έχουν οποιαδήποτε διακριτόκλινικό αποτέλεσμα, μια μικρή μείωση στη φαρμακοδυναμική ισχύ της κλοπιδογρέλης θα μπορούσε να οδηγήσει σε σοβαρές ισχαιμικές θρομβωτικές επιπλοκές, ιδιαίτερα σε καταστάσεις όπου η θεραπευτική αποτελεσματικότητα είναι κρίσιμη, όπως αμέσως μετά από μια διαδερμική στεφανιαία παρέμβαση. Η ανάγκη για την αξιολόγηση της θεραπευτικής αποτελεσματικότητας ενός γενόσημου άλατος κλοπιδογρέλης υποστηρίζεται περαιτέρω από τη σημαντική ετερογένεια μεταξύ των υφιστάμενων γενόσημων σκευασμάτων κλοπιδογρέλης, όσον αφορά το περιεχόμενο της κλοπιδογρέλης, το προφίλ καθαρότητας, τις ιδιότητες διάλυσης και σταθερότητας, ακόμη και αν αυτές αφορούν το ίδιο το άλας. Έως σήμερα έχει διεξαχθεί μια σειρά από μικρές και συχνά χαμηλής ισχύος μελέτες που συγκρίνουν είτε φαρμακοδυναμικά είτε κλινικά καταληκτικά σημεία σε ασθενείς που λαμβάνουν γενόσημα έναντι της πρωτότυπης κλοπιδογρέλης. Μεταξύ αυτών πολύ λίγες είναι οι μελέτες που χρησιμοποιούν μείζονα καταληκτικά συμβάντα και παρακολούθηση ασθενών για περισσότερο από 3 μήνες, ενώ πολλές δοκιμές διεξήχθησαν σε υγιείς εθελοντές. Η ερευνητική μας ομάδα είχε δημοσιεύσει δύο μελέτες οι οποίες κατέληξαν στο συμπέρασμα ότι υπήρξε φαρμακοδυναμική βιοϊσοδυναμία μεταξύ του γενόσημου σκευάσματος CB σε σχέση με εκείνο του πρωτότυπου σκευάσματος CHS σε ασθενείς με 1 και 6 μήνες παρακολούθησης μετά από οξύ στεφανιαίο σύνδρομο. ΣΚΟΠΟΣ: O σκοπός της παρούσας μελέτης ήταν να συγκριθεί η κλινική αποτελεσματικότητα και ασφάλεια του σκευάσματος CB σε σχέση με εκείνητης πρωτότυπης CHS, που χορηγήθηκαν για 12 μήνες σε ένα σχετικά μεγάλο αριθμό ασθενών που μπορούν να λάβουν κλοπιδογρέλη σύμφωνα με τις ενδείξεις και τις κατευθυντήριες οδηγίες. Η ενδιάμεση ανάλυση αυτής της μελέτης έγινε στους 6 μήνες παρακολούθησης. ΜΕΘΟΔΟΙ: Διενεργήθηκε μια τυχαιοποιημένη προοπτική 2-βραχίονων, πολυκεντρική, ανοικτή, φάσης 4 κλινική μελέτη, που ονομάστηκε Salts of Clopidogrel: Investigation to EN sure Clinical Equivalence (SCIENCE). Κατά τη διάρκεια της μελέτης αυτής 1864 διαδοχικοί ασθενείς ελέγχθηκαν και 1800 καταγράφηκαν στη μελέτη και τυχαιοποιήθηκαν σε CHS ή CB. Πρωτεύον καταληκτικό σημείο αποτελεσματικότητας ήταν το σύνθετο του εμφράγματος του μυοκαρδίου, ΑΕΕ ή θανάτου από αγγειακά αίτια, και πρωτεύον καταληκτικό σημείο ασφάλειας ήταν η συχνότητα των αιμορραγικών επεισοδίων, όπως ορίζεται από τα αιμορραγικά κριτήρια Bleeding Academic Research Consortium (BARC) ΑΠΟΤΕΛΕΣΜΑΤΑ: Στους 6 μήνες παρακολούθησης δεν παρατηρήθηκαν διαφορές μεταξύ των CB(n=759) και CHS (n=798) στο πρωτεύον καταληκτικό σημείο αποτελεσματικότητας (OR, 0.80; 95% CI, 0.37 to 1.71; p=0.57). Ποσοστά αιμορραγίας BARC-1, -2, -3a και -5b ήταν παρόμοια μεταξύ των δύο ομάδων της μελέτης, ενώ δεν παρατηρήθηκαν αιμορραγικά συμβάντα BARC-3b, -3c,-4 και -5a είτε στη CHS είτε στη CB ομάδα. Στους 12 μήνες παρακολούθησης, δεν παρατηρήθηκαν διαφορές μεταξύ των CB και CHS στα πρωτεύοντα καταληκτικά σημεία αποτελεσματικότητας και ασφάλειας (προσαρμοσμένο ποσοστό πιθανότητας για ηλικία, φύλο, ιστορικό διαδερμικής στεφανιαίας αγγειοπλαστικής [OR], 0.70; 95% διάστημα εμπιστοσύνης [CI], 0.41-1.21 καιOR, 0.81; 95% CI, 0.51-1.29 αντίστοιχα). Αναλύσεις αποτελεσματικότητας και ασφάλειας σε υποομάδες οι οποίες καθορίζονταν σύμφωνα με την ειδική διάγνωση κατέληξαν στο ότι δεν υπήρχε διαφορά μεταξύ CHS και CB. ΣΥΜΠΕΡΑΣΜΑ: Η παρούσα κλινική μελέτη κατέληξε στο συμπέρασμα ότι η κλινική αποτελεσματικότητα του άλατος της CB που χορηγείται για 12 μήνες σε διάφορες κατηγορίες ασθενών που μπορούν να λάβουν κλοπιδογρέλη είναι παρόμοια με εκείνη του πρωτότυπου άλατος της CHS. Επιπλέον και τα δυο άλατα κλοπιδογρέλης επέδειξαν παρόμοιο προφίλ ασφάλειας. Η ενδιάμεση ανάλυση αυτής της μελέτης που διεξήχθη στους 6 μήνες παρακολούθησης έδειξε επίσης ότι δεν υπήρχαν διαφορές στα κλινικά πρωτεύοντα και δευτερεύοντα καταληκτικά σημεία αοτελεσματικότητας και ασφάλειας μεταξύ CB και CHS. Σύμφωνα με τα δεδομένα μας αυτή είναι η μεγαλύτερη κλινική μελέτη που πραγματοποιήθηκε μέχρι σήμερα από την άποψη τουμεγέθους του πληθυσμού, τη διάρκεια της μελέτης και τις υπο ομάδες ασθενών,με στόχο να συγκριθεί η αποτελεσματικότητα και η ασφάλεια ενός γενόσημου άλατος κλοπιδογρέλης με το πρωτότυπο σκεύασμα κλοπιδογρέλης στη δευτερογενή πρόληψη των αθηροθρομβωτικών επεισοδίων. (Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence, SCIENCE trial; ClinicalTrials.gov Identifier: NCT02126982). Ευχαριστίες (Χορηγίες/ Οικονομική ενίσχυση):Η μελέτη αυτή χρηματοδοτήθηκε εν μέρει από την Ευρωπαϊκή Ένωση και μέσω του Επιχειρησιακού Προγράμματος «Ανταγωνιστικότητα και Επιχειρηματικότητα» του Εθνικού Στρατηγικού Πλαισίου Αναφοράς (ΕΣΠΑ)–Ερευνητικό Πρόγραμμα Χρηματοδότησης: Συνεργασία 2009. Δράση Ι. Συνεταιρισμός μικρής και μεσαίας κλίμακας (κωδικός έργου: 09ΣΥΝ-12-827) και από την επιτροπή ερευνών μέσω του ειδικού λογαριασμού κονδυλίων έρευνας (ΕΛΚΕ) του Πανεπιστημίου Ιωαννίνων. Η μελέτη αυτή επίσης χρηματοδοτήθηκε εν μέρει από την ELPEN (Ελλάδα), κατασκευάστρια εταιρεία του σκευάσματος της βεσυλικής κλοπιδογρέλης (Clovelen®) που χρησιμοποιήθηκε στην παρούσα μελέτη. Ωστόσο, ο χορηγός δεν είχε καμία συμμετοχή στο σχεδιασμό και τη διεξαγωγή της μελέτης, κατά τη συλλογή, διαχείριση, ανάλυση και ερμηνεία των δεδομένων ή στην προετοιμασία, διόρθωση, υποβολή και έγκριση των δημοσιευμένων άρθρων.
- Published
- 2021
12. Updated knowledge and practical implementations of stress echocardiography in ischemic and non-ischemic cardiac diseases: An expert consensus of the Working Group of Echocardiography of the Hellenic Society of Cardiology
- Author
-
Nikolaos P.E. Kadoglou, Constantinos H. Papadopoulos, Konstantinos G. Papadopoulos, Stefanos Karagiannis, Ilias Karabinos, Savvas Loizos, Anastasios Theodosis-Georgilas, Konstantina Aggeli, Kalliopi Keramida, Dimitrios Klettas, Stavros Kounas, George Makavos, Ilias Ninios, Ioannis Ntalas, Ignatios Ikonomidis, Vasilios Sahpekidis, Alexandros Stefanidis, Theodora Zaglavara, George Athanasopoulos, George Karatasakis, Stamatios Kyrzopoulos, Nikos Kouris, Alexandros Patrianakos, Ioannis Paraskevaidis, Loukianos Rallidis, Konstantinos Savvatis, Dimitrios Tsiapras, and Petros Nihoyannopoulos
- Subjects
medicine.medical_specialty ,Consensus ,Heart Diseases ,business.industry ,valvular heart disease ,Cardiomyopathy ,Cardiology ,Expert consensus ,medicine.disease ,Coronary artery disease ,Echocardiography ,Heart failure ,Internal medicine ,Stress Echocardiography ,Medicine ,Humans ,Non ischemic ,Cardiology and Cardiovascular Medicine ,business ,Medical literature ,Echocardiography, Stress - Abstract
Stress echocardiography (SE) is a well-established and valid technique, widely-used for the diagnostic evaluation of patients with ischemic and non-ischemic cardiac diseases. This statement of the Echocardiography Working Group of the Hellenic Society of Cardiology summarizes the consensus of the writing group regarding the applications of SE, based on the expertise of their members and on a critical review of current medical literature. The main objectives of the consensus document include a comprehensive review of SE methodology and training, focusing on the preparation, the protocols used and the analysis of the SE images and an updated, evidence-based knowledge about SE applications on ischemic and non-ischemic heart diseases, such as in cardiomyopathies, heart failure and valvular heart disease.
- Published
- 2021
13. Emerging role of cardiac computed tomography in heart failure
- Author
-
Daniel Toth, Reza Razavi, Christopher A. Rinaldi, Peter Mountney, Steven A. Niederer, Justin Gould, Ioannis Ntalas, Waqar Aziz, Rebecca Preston, Orod Razeghi, Simon Claridge, Adelaide de Vecchi, and Ronak Rajani
- Subjects
medicine.medical_specialty ,lcsh:Diseases of the circulatory (Cardiovascular) system ,Cardiac computed tomography ,Cardiomyopathy ,Computer processing ,Reviews ,Heart failure ,Bioengineering ,Review ,030204 cardiovascular system & hematology ,03 medical and health sciences ,CT fusion ,0302 clinical medicine ,Cardiac magnetic resonance imaging ,medicine ,Humans ,030212 general & internal medicine ,medicine.diagnostic_test ,business.industry ,Myocardial Perfusion Imaging ,Stroke Volume ,CT dyssynchrony ,medicine.disease ,Prognosis ,Magnetic Resonance Imaging ,Echocardiography ,lcsh:RC666-701 ,Female ,Radiology ,Cardiac Electrophysiology ,Cardiology and Cardiovascular Medicine ,business ,Cardiomyopathies ,Tomography, X-Ray Computed - Abstract
Despite medical advancements, the prognosis of patients with heart failure remains poor. While echocardiography and cardiac magnetic resonance imaging remain at the forefront of diagnosing and monitoring patients with heart failure, cardiac computed tomography (CT) has largely been considered to have a limited role. With the advancements in scanner design, technology, and computer processing power, cardiac CT is now emerging as a valuable adjunct to clinicians managing patients with heart failure. In the current manuscript, we review the current applications of cardiac CT to patients with heart failure and also the emerging areas of research where its clinical utility is likely to extend into the realm of treatment, procedural planning, and advanced heart failure therapy implementation.
- Published
- 2019
14. Non-invasive fractional flow reserve using computed tomographic angiography: where are we now and where are we going?
- Author
-
Bhavik Modi, Nick Curzen, Ioannis Ntalas, and Ronak Rajani
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,Computed Tomography Angiography ,business.industry ,Functional testing ,Coronary Artery Disease ,Fractional flow reserve ,Disease ,030204 cardiovascular system & hematology ,medicine.disease ,Chest pain ,Fractional Flow Reserve, Myocardial ,Computed tomographic angiography ,Coronary artery disease ,03 medical and health sciences ,0302 clinical medicine ,Angiography ,Humans ,Medicine ,030212 general & internal medicine ,Radiology ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Computed tomography angiography - Abstract
Learning objectives Coronary computed tomographic angiography (CTA) is now established as a clinically valuable non-invasive anatomical test for the detection and exclusion of significant coronary disease. A number of prospective multicentre trials have shown coronary CTA to be an ideal test for the exclusion and detection of coronary disease using invasive angiography as the reference.1–3 Despite this, owing to its relatively low positive predictive value of 48% and inability to determine functional significance,1 its use in international guidelines has generally been restricted to patients with chest pain at a low-intermediate risk of having coronary artery disease (CAD).4 For patients at an intermediate risk of CAD, functional testing is generally indicated, and for high-risk patients, invasive coronary angiography (ICA) remains the recommended diagnostic test. Although this strategy is designed to determine whether a patient’s symptoms are attributable to CAD, and specifically myocardial ischaemia, recent studies indicate that this approach has important flaws. In a study of almost 400 000 patients, Patel et al showed that up to 62% of the patients who underwent ICA in the USA were subsequently found to have no significant obstructive disease. Furthermore, of those patients with a positive stress test, approximately two-thirds had no obstructive disease and, conversely, 28% of the patients with a negative stress …
- Published
- 2017
15. Advanced atrioventricular block with a very prolonged ventricular asystole detected four hours after placement of an impantable loop recorder
- Author
-
John A. Goudevenos, Panagiotis Korantzopoulos, Ioannis Ntalas, and M. I. Papafaklis
- Subjects
medicine.medical_specialty ,Heart disease ,business.industry ,General Engineering ,Syncopal episodes ,medicine.disease ,Advanced Atrioventricular Block ,High grade atrioventricular block ,Anesthesia ,Internal medicine ,medicine ,Cardiology ,Implantable loop recorder ,Ventricular asystole ,Asystole ,business ,Loop recorder - Abstract
In this report, we present a 42-year-old woman without structural heart disease who underwent an implantable loop recorder implantation for recurrent syncopal episodes during the past 12 years. Four hours after implantation, the patient suffered sudden loss of consciousness while sitting on her bed in the ward. Interestingly, interrogation of the device revealed an episode of advanced atrioventricular block with a very prolonged ventricular asystole of 25 sec. We also provide a concise overview of the literature regarding the implantable loop recorder use in recurrent unexplained syncope as well as regarding idiopathic advanced atrioventricular block.
- Published
- 2016
16. Clinical value of dark-blood late gadolinium enhancement cardiovascular magnetic resonance without additional magnetization preparation
- Author
-
Muhummad Sohaib Nazir, René M. Botnar, Ioannis Ntalas, Amedeo Chiribiri, Robert J. Holtackers, Imran Rashid, Haseeb Rahman, Caroline M. Van De Heyning, Promovendi CD, Beeldvorming, MUMC+: DA BV Research (9), RS: CARIM - R3.11 - Imaging, and RS: Carim - B06 Imaging
- Subjects
Male ,lcsh:Diseases of the circulatory (Cardiovascular) system ,Myocardial Ischemia ,Contrast Media ,Late gadolinium enhancement ,DISEASE ,030218 nuclear medicine & medical imaging ,Late enhancement ,0302 clinical medicine ,Myocardial infarction ,Observer Variation ,Radiological and Ultrasound Technology ,medicine.diagnostic_test ,LGE ,Middle Aged ,embryonic structures ,Subendocardial scar ,Cardiology ,SURVIVAL ,Female ,Cardiology and Cardiovascular Medicine ,Cardiomyopathies ,Adult ,medicine.medical_specialty ,Dark-blood ,CONTRAST ,Magnetic Resonance Imaging, Cine ,Inversion recovery ,03 medical and health sciences ,Cicatrix ,Predictive Value of Tests ,Internal medicine ,medicine ,Organometallic Compounds ,Humans ,Radiology, Nuclear Medicine and imaging ,cardiovascular diseases ,Thrombus ,Angiology ,Aged ,INVERSION-RECOVERY ,Tissue Survival ,Computer. Automation ,business.industry ,Myocardium ,Research ,Reproducibility of Results ,Magnetic resonance imaging ,medicine.disease ,Myocardial scar ,MYOCARDIAL-INFARCTION ,lcsh:RC666-701 ,Dark blood ,Clinical value ,Human medicine ,business - Abstract
BACKGROUND: For two decades, bright-blood late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) has been considered the reference standard for the non-invasive assessment of myocardial viability. While bright-blood LGE can clearly distinguish areas of myocardial infarction from viable myocardium, it often suffers from poor scar-to-blood contrast, making subendocardial scar difficult to detect. Recently, we proposed a novel dark-blood LGE approach that increases scar-to-blood contrast and thereby improves subendocardial scar conspicuity. In the present study we sought to assess the clinical value of this novel approach in a large patient cohort with various non-congenital ischemic and non-ischemic cardiomyopathies on both 1.5 T and 3 T CMR scanners of different vendors.METHODS: Three hundred consecutive patients referred for clinical CMR were randomly assigned to a 1.5 T or 3 T scanner. An entire short-axis stack and multiple long-axis views were acquired using conventional phase sensitive inversion recovery (PSIR) LGE with TI set to null myocardium (bright-blood) and proposed PSIR LGE with TI set to null blood (dark-blood), in a randomized order. The bright-blood LGE and dark-blood LGE images were separated, anonymized, and interpreted in a random order at different time points by one of five independent observers. Each case was analyzed for the type of scar, per-segment transmurality, papillary muscle enhancement, overall image quality, observer confidence, and presence of right ventricular scar and intraventricular thrombus.RESULTS: Dark-blood LGE detected significantly more cases with ischemic scar compared to conventional bright-blood LGE (97 vs 89, p = 0.008), on both 1.5 T and 3 T, and led to a significantly increased total scar burden (3.3 ± 2.4 vs 3.0 ± 2.3 standard AHA segments, p = 0.015). Overall image quality significantly improved using dark-blood LGE compared to bright-blood LGE (81.3% vs 74.0% of all segments were of highest diagnostic quality, p = 0.006). Furthermore, dark-blood LGE led to significantly higher observer confidence (confident in 84.2% vs 78.4%, p = 0.033).CONCLUSIONS: The improved detection of ischemic scar makes the proposed dark-blood LGE method a valuable diagnostic tool in the non-invasive assessment of myocardial scar. The applicability in routine clinical practice is further strengthened, as the present approach, in contrast to other recently proposed dark- and black-blood LGE techniques, is readily available without the need for scanner adjustments, extensive optimizations, or additional training.
- Published
- 2019
17. A Kaleidoscope heart
- Author
-
Ioannis Ntalas, Abigail Gowland, Ronak Rajani, and Dario Freitas
- Subjects
medicine.medical_specialty ,Adolescent ,Computed tomography ,030204 cardiovascular system & hematology ,Coronary Angiography ,Sudden cardiac death ,Diagnosis, Differential ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Bland White Garland Syndrome ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,030212 general & internal medicine ,Unusual case ,medicine.diagnostic_test ,business.industry ,Coronary artery ectasia ,Coronary ct angiography ,Heart ,Color doppler ,medicine.disease ,Echocardiography, Doppler, Color ,Heart Arrest ,medicine.anatomical_structure ,cardiovascular system ,Cardiology ,Female ,Transthoracic echocardiogram ,Cardiology and Cardiovascular Medicine ,business ,Artery - Abstract
In the current manuscript, we report an unusual case of a young 18-year-old woman who survived an out-of-hospital cardiac arrest secondary to Bland-White-Garland syndrome. Her transthoracic echocardiogram showed an abnormal color Doppler flow-pattern within the myocardium indicative of coronary fistulous flow that prompted further evaluation with coronary CT angiography, which confirmed the diagnosis. Our case serves not only as a reminder to consider coronary artery anomalies as a cause of sudden cardiac death in young individuals but also as a prompt to investigate unusual echocardiographic findings with alternative imaging when the diagnosis may not be initially clear.
- Published
- 2018
18. Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial
- Author
-
Leonidas Peltekis, Ioannis Efthimiadis, Nikolaos Prokopakis, Zaharias Christogiannis, Maria Voukelatou, Maria Thoma, Ioannis Sinteles, Adamantios Bourdakis, Alexandros D. Tselepis, Maria E. Tsoumani, Haralampos J. Milionis, Ioannis Giatrakos, Giorgos Hatziathanasiou, Spiros Konstantinou, Nikolaos Kipouridis, Kyriafina Terzoudi, Demosthenes B. Panagiotakos, Konstantinos Vemmos, Evangelos Kazakos, Christos Charmpas, Dimitrios Nikolopoulos, Ioannis Vakalis, Ioannis Ntalas, John A. Goudevenos, Antonios Draganigos, Vassilios Giogiakas, Ioannis Xaraktsis, Giorgos Giannakoulas, Christos S. Stroumbis, Giorgos Goumas, Konstantinos Vardakis, Vasileios Vasilakopoulos, Nikolaos Dimoulis, Karmelos Tsilias, and Kallirroi I Kalantzi
- Subjects
Male ,Time Factors ,medicine.medical_treatment ,Myocardial Infarction ,Kaplan-Meier Estimate ,030204 cardiovascular system & hematology ,law.invention ,Coronary artery disease ,0302 clinical medicine ,Randomized controlled trial ,Risk Factors ,law ,Odds Ratio ,Secondary Prevention ,Pharmacology (medical) ,Prospective Studies ,030212 general & internal medicine ,Myocardial infarction ,Aged, 80 and over ,Greece ,Middle Aged ,Clopidogrel ,Stroke ,Treatment Outcome ,Cardiovascular Diseases ,Female ,Cardiology and Cardiovascular Medicine ,medicine.drug ,medicine.medical_specialty ,Ticlopidine ,Drug Compounding ,Hemorrhage ,03 medical and health sciences ,Percutaneous Coronary Intervention ,Internal medicine ,medicine ,Drugs, Generic ,Humans ,Aged ,Pharmacology ,business.industry ,Percutaneous coronary intervention ,Odds ratio ,medicine.disease ,Confidence interval ,Surgery ,Clinical trial ,Therapeutic Equivalency ,business ,Platelet Aggregation Inhibitors - Abstract
Background: In the present clinical trial, we compared the efficacy and safety of the generic clopidogrel besylate (CB) with the innovator clopidogrel hydrogen sulfate (CHS) salt in patients eligible to receive clopidogrel. Methods: A prospective 2-arm, multicenter, open-label, phase 4 clinical trial. Consecutive patients (n = 1864) were screened and 1800 were enrolled in the trial and randomized to CHS or CB. Primary efficacy end point was the composite of myocardial infarction, stroke, or death from vascular causes, and primary safety end point was rate of bleeding events as defined by Bleeding Academic Research Consortium criteria. Results: At 12-month follow-up, no differences were observed between CB (n = 759) and CHS (n = 798) in primary efficacy and safety end points (age, sex, history of percutaneous coronary intervention adjusted odds ratio [OR], 0.70; 95% confidence interval [CI], 0.41-1.21 and OR, 0.81; 95% CI, 0.51-1.29, respectively) between CHS and CB. Analyses of efficacy and safety in subgroups that were defined according to the qualifying diagnosis revealed that there was no difference between CHS and CB. Conclusion: The efficacy and safety of CB administered for 12 months for the secondary prevention of atherothrombotic events are similar to that of CHS. (Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence, SCIENCE trial; ClinicalTrials.gov Identifier:NCT02126982).
- Published
- 2016
19. Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy
- Author
-
Ioannis Ntalas, John A. Goudevenos, Alexandros D. Tselepis, Prokopia T. Tatsidou, and Maria E. Tsoumani
- Subjects
Blood Platelets ,Male ,0301 basic medicine ,Ticagrelor ,Acute coronary syndrome ,Adenosine ,Ticlopidine ,Platelet Aggregation ,Platelet Function Tests ,030204 cardiovascular system & hematology ,Pharmacology ,03 medical and health sciences ,Platelet Adhesiveness ,0302 clinical medicine ,Platelet adhesiveness ,medicine ,Humans ,Platelet ,Acute Coronary Syndrome ,Aged ,Aspirin ,business.industry ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,Clopidogrel ,Treatment Outcome ,030104 developmental biology ,Case-Control Studies ,Anesthesia ,Platelet aggregation inhibitor ,Female ,business ,Biomarkers ,Platelet Aggregation Inhibitors ,medicine.drug - Abstract
Platelet adhesion and aggregation are key functions leading to thrombus formation. The effect of aspirin, clopidogrel, and ticagrelor on platelet aggregation has been well established, however, there is limited data on the effect of these drugs on platelet adhesion. We therefore evaluated the effect of these drugs on platelet adhesion in acute coronary syndrome (ACS) patients. Citrated blood was collected from 50 ACS patients loaded with 325 mg of aspirin (baseline) and at 5 days after the administration of aspirin 100 mg/day and clopidogrel (600 mg loading dose, 75 mg/day) (n = 26) or ticagrelor (180 mg loading dose, 90 mg × 2/day) (n = 24). High on-treatment platelet reactivity (HTPR) to clopidogrel was estimated by vasodilator stimulated phosphoprotein (VASP) phosphorylation assay. Platelet adhesion to collagen was studied for 6 min under high shear stress and was evaluated using the time to platelet recruitment (TPR), the perimeter and average area of each adherent object, number of adherent objects, and the total percent of surface coverage (SC%). Six ACS patients exhibited HTPR to clopidogrel and excluded from the platelet adhesion assays. TPR and SC% values were similar among patient groups at baseline and controls. However, all other adhesion parameters were different in ACS patients, indicating the formation of more aggregates in regard to controls. At 5 days post-treatment with either clopidogrel or ticagrelor, the TPR values were increased and the SC% values were reduced to a similar extent compared with baseline. However, significant differences were observed in the ticagrelor group in the perimeter, number of adherent objects, and the average area of each adherent object indicating a more potent inhibition of adherence-induced platelet aggregation than clopidogrel. In conclusion, aspirin does not affect platelet adherence to collagen, whereas clopidogrel and ticagrelor inhibit to a similar extent dynamic platelet adhesion at 5 days post-treatment in ACS patients. However, ticagrelor exhibits a greater inhibitory effect on reducing adhesion-induced platelet aggregation.
- Published
- 2016
20. Obesity and atrial fibrillation: A comprehensive review of the pathophysiological mechanisms and links
- Author
-
Panagiotis Korantzopoulos, Dimitrios G. Ketikoglou, Eleftherios M. Kallergis, Christos A. Goudis, and Ioannis Ntalas
- Subjects
medicine.medical_specialty ,Diastole ,Coronary Artery Disease ,Coronary artery disease ,Internal medicine ,Diabetes mellitus ,Epicardial adipose tissue ,Atrial Fibrillation ,Diabetes Mellitus ,medicine ,Humans ,Ventricular Function ,Heart Atria ,Obesity ,Metabolic Syndrome ,Sleep Apnea, Obstructive ,business.industry ,Atrial fibrillation ,Atrial Remodeling ,medicine.disease ,Pathophysiology ,Obstructive sleep apnea ,Hypertension ,Cardiology ,Metabolic syndrome ,Cardiology and Cardiovascular Medicine ,business ,Pericardium - Abstract
Obesity is a worldwide health problem with epidemic proportions that has been associated with atrial fibrillation (AF). Even though the underlying pathophysiological mechanisms have not been completely elucidated, several experimental and clinical studies implicate obesity in the initiation and perpetuation of AF. Of note, hypertension, diabetes mellitus, metabolic syndrome, coronary artery disease, and obstructive sleep apnea, represent clinical correlates between obesity and AF. In addition, ventricular adaptation, diastolic dysfunction, and epicardial adipose tissue appear to be implicated in atrial electrical and structural remodeling, thereby promoting the arrhythmia in obese subjects. The present article provides a concise overview of the association between obesity and AF, and highlights the underlying pathophysiological mechanisms.
- Published
- 2015
21. Electrocardiographic abnormalities and cardiac arrhythmias in chronic obstructive pulmonary disease
- Author
-
Christos A. Goudis, Ioannis Ntalas, Panagiotis Korantzopoulos, and Athanasios Konstantinidis
- Subjects
COPD ,medicine.medical_specialty ,Premature atrial contraction ,business.industry ,Atrial fibrillation ,medicine.disease ,Ventricular tachycardia ,Coronary artery disease ,Internal medicine ,Heart failure ,cardiovascular system ,medicine ,Cardiology ,cardiovascular diseases ,Cardiology and Cardiovascular Medicine ,business ,Multifocal atrial tachycardia ,Atrial flutter - Abstract
Chronic obstructive pulmonary disease (COPD) is independently associated with an increased burden of cardiovascular disease. Besides coronary artery disease (CAD) and congestive heart failure (CHF), specific electrocardiographic (ECG) abnormalities and cardiac arrhythmias seem to have a significant impact on cardiovascular prognosis of COPD patients. Disturbances of heart rhythm include premature atrial contractions (PACs), premature ventricular contractions (PVCs), atrial fibrillation (AF), atrial flutter (AFL), multifocal atrial tachycardia (MAT), and ventricular tachycardia (VT). Of note, the identification of ECG abnormalities and the evaluation of the arrhythmic risk may have significant implications in the management and outcome of patients with COPD. This article provides a concise overview of the available data regarding ECG abnormalities and arrhythmias in these patients, including an elaborated description of the underlying arrhythmogenic mechanisms. The clinical impact and prognostic significance of ECG abnormalities and arrhythmias in COPD as well as the appropriate antiarrhythmic therapy and interventions in this setting are also discussed.
- Published
- 2015
22. Automated quantification of mitral valve geometry on multi-slice computed tomography in patients with dilated cardiomyopathy: Implications for transcatheter mitral valve replacement
- Author
-
Ronak Rajani, Bernard Prendergast, Simon Redwood, Rebecca Preston, Ioannis Ntalas, Orod Razeghi, Tom Banks, Brian Campbell, Jonathan M. Behar, Waqar Aziz, and Steven A. Niederer
- Subjects
Cardiomyopathy, Dilated ,Male ,Cardiac Catheterization ,medicine.medical_treatment ,Diastole ,Cardiac-Gated Imaging Techniques ,Geometry ,Computed tomography ,030204 cardiovascular system & hematology ,03 medical and health sciences ,Automation ,Electrocardiography ,0302 clinical medicine ,Predictive Value of Tests ,Mitral valve ,Multidetector Computed Tomography ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Mitral Valve Annulus ,030212 general & internal medicine ,cardiovascular diseases ,Aged ,Retrospective Studies ,Aged, 80 and over ,Heart Valve Prosthesis Implantation ,Mitral regurgitation ,medicine.diagnostic_test ,Cardiac cycle ,business.industry ,Mitral valve replacement ,Hemodynamics ,Mitral Valve Insufficiency ,Reproducibility of Results ,Dilated cardiomyopathy ,Middle Aged ,medicine.disease ,medicine.anatomical_structure ,cardiovascular system ,Mitral Valve ,Radiographic Image Interpretation, Computer-Assisted ,Female ,Cardiology and Cardiovascular Medicine ,business ,Algorithms ,Transcatheter mitral valve replacement - Abstract
Objectives The primary aim of this study was to quantify the dimensions and geometry of the mitral valve complex in patients with dilated cardiomyopathy and significant mitral regurgitation. The secondary aim was to evaluate the validity of an automated segmentation algorithm for assessment of the mitral valve compared to manual assessment on computed tomography. Background Transcatheter mitral valve replacement (TMVR) is an evolving technique which relies heavily on the lengthy evaluation of cardiac computed tomography (CT) datasets. Limited data is available on the dimensions and geometry of the mitral valve in pathological states throughout the cardiac cycle, which may have implications for TMVR device design, screening of suitable candidates and annular sizing prior to TMVR. Methods A retrospective study of 15 of patients with dilated cardiomyopathy who had undergone full multiphase ECG gated cardiac CT. A comprehensive evaluation of mitral valve geometry was performed at 10 phases of the cardiac cycle using the recommended D-shaped mitral valve annulus (MA) segmentation model using manual and automated CT interpretation platforms. Mitral annular dimensions and geometries were compared between manual and automated methods. Results Mitral valve dimensions in patients with dilated cardiomyopathy were similar to previously reported values (MAarea Diastole: 12.22 ± 1.90 cm2), with dynamic changes in size and geometry between systole and diastole of up to 5%. The distance from the centre of the MA to the left ventricular apex demonstrated moderate agreement between automated and manual methods (ρc = 0.90) with other measurements demonstrating poor agreement between the two methods (ρc = 0.75–0.86). Conclusions Variability of mitral valve annulus measurements are small during the cardiac cycle. Novel automated algorithms to determine cardiac cycle variations in mitral valve geometry may offer improved segmentation accuracy as well as improved CT interpretation times.
- Published
- 2018
23. Computed Tomography Aortic Valve Calcium Scoring in Patients With Aortic Stenosis
- Author
-
Tania Pawade, Marie-Annick Clavel, Christophe Tribouilloy, Julien Dreyfus, Tiffany Mathieu, Lionel Tastet, Cedric Renard, Mesut Gun, William Steven Arthur Jenkins, Laurent Macron, Jacob W. Sechrist, Joan M. Lacomis, Virginia Nguyen, Laura Galian Gay, Hug Cuéllar Calabria, Ioannis Ntalas, Timothy Robert Graham Cartlidge, Bernard Prendergast, Ronak Rajani, Arturo Evangelista, João L. Cavalcante, David E. Newby, Philippe Pibarot, David Messika Zeitoun, and Marc R. Dweck
- Subjects
Male ,Aortic valve ,medicine.medical_specialty ,030204 cardiovascular system & hematology ,Severity of Illness Index ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Aortic valve replacement ,Internal medicine ,Multidetector Computed Tomography ,Severity of illness ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,Registries ,Prospective cohort study ,Aged ,Aged, 80 and over ,business.industry ,Hazard ratio ,Calcinosis ,Aortic Valve Stenosis ,Prognosis ,medicine.disease ,Echocardiography, Doppler ,Confidence interval ,Stenosis ,medicine.anatomical_structure ,Aortic Valve ,Heart Valve Prosthesis ,Aortic valve stenosis ,Cardiology ,Calcium ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background— Computed tomography aortic valve calcium scoring (CT-AVC) holds promise for the assessment of patients with aortic stenosis (AS). We sought to establish the clinical utility of CT-AVC in an international multicenter cohort of patients. Methods and Results— Patients with AS who underwent ECG-gated CT-AVC within 3 months of echocardiography were entered into an international, multicenter, observational registry. Optimal CT-AVC thresholds for diagnosing severe AS were determined in patients with concordant echocardiographic assessments, before being used to arbitrate disease severity in those with discordant measurements. In patients with long-term follow-up, we assessed whether CT-AVC thresholds predicted aortic valve replacement and death. In 918 patients from 8 centers (age, 77±10 years; 60% men; peak velocity, 3.88±0.90 m/s), 708 (77%) patients had concordant echocardiographic assessments, in whom CT-AVC provided excellent discrimination for severe AS (C statistic: women 0.92, men 0.89). Our optimal sex-specific CT-AVC thresholds (women 1377 Agatston unit and men 2062 Agatston unit) were nearly identical to those previously reported (women 1274 Agatston unit and men 2065 Agatston unit). Clinical outcomes were available in 215 patients (follow-up 1029 [126–2251] days). Sex-specific CT-AVC thresholds independently predicted aortic valve replacement and death (hazard ratio, 3.90 [95% confidence interval, 2.19–6.78]; P P =0.010). Conclusions— Sex-specific CT-AVC thresholds accurately identify severe AS and provide powerful prognostic information. These findings support their integration into routine clinical practice. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifiers: NCT01358513, NCT02132026, NCT00338676, NCT00647088, NCT01679431.
- Published
- 2018
24. Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial
- Author
-
Maria Thoma, Alexandros D. Tselepis, Konstantinos Mavronasos, Dimitrios Logothetis, Konstantina Martiadou, Petros Darmanis, Konstantinos Ipeirotis, Stefanos Gkiokas, Christos Asimakopoulos, Demosthenes B. Panagiotakos, Maria E. Tsoumani, Stergios Zisekas, Miltiadis Papaioakeim, Dimitrios Adamopoulos, Ioannis Klonaris, Alexandros Zenetos, Dimitrios V. Stergiou, Georgios Papadimitriou, Kyriaki Kitikidou, Vasileios G. Chantzichristos, Alexandra Dimitriadou, Theodoros Mais, Emmanouil Stefanakis, Kallirroi I Kalantzi, Ioannis Ntalas, Kosmas Sofillas, Athanasios Maragiannis, Konstantinos Mainas, Dimitrios Mitropoulos, Achilleas Papadopoulos, Aglaia Kostaki, John A. Goudevenos, Adamantios Bourdakis, Sotiria Stabola, and Ioannis Michelongonas
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Myocardial Infarction ,Hemorrhage ,Coronary Artery Disease ,030204 cardiovascular system & hematology ,Brain Ischemia ,Coronary artery disease ,03 medical and health sciences ,0302 clinical medicine ,Recurrence ,Risk Factors ,Internal medicine ,Secondary Prevention ,Medicine ,Humans ,Cyclooxygenase Inhibitors ,030212 general & internal medicine ,Myocardial infarction ,Stroke ,Aged ,Pharmacology ,Aspirin ,Greece ,business.industry ,Incidence (epidemiology) ,Middle Aged ,medicine.disease ,Confidence interval ,Salicylates ,Clinical trial ,Treatment Outcome ,Intracranial Embolism ,Triflusal ,Female ,Cardiology and Cardiovascular Medicine ,business ,Platelet Aggregation Inhibitors ,medicine.drug - Abstract
Background: Triflusal has demonstrated an efficacy similar to aspirin in the prevention of vascular events in patients with acute myocardial infarction (ΜΙ) and ischaemic stroke but with less bleeding events. Objective: We performed a randomised, multicentre, phase 4 clinical trial to compare the clinical efficacy and safety of triflusal versus aspirin, administered for 12 months in patients eligible to receive a cyclooxygenase-1 (COX-1) inhibitor. Methods: Patients with stable coronary artery disease or with a history of non-cardioembolic ischaemic stroke were randomly assigned to receive either triflusal 300 mg twice or 600 mg once daily or aspirin 100 mg once daily for 12 months. The primary efficacy endpoint was the composite of: (a) ΜΙ, (b) stroke (ischaemic or haemorrhagic), or, (c) death from vascular causes for the entire follow-up period. The primary safety endpoints were the rate of bleeding events as defined by Bleeding Academic Research Consortium (BARC) criteria. Results: At 12-month follow-up, an equivalent result was revealed between the triflusal (n=559) and aspirin (n=560) in primary efficacy endpoint. Specifically, the combined efficacy outcome rate (i.e. MI, stroke or death from vascular causes) difference was equal to -1.3% (95% confidence interval -1.1 to 3.5) and lied within the a-priori defined equivalence interval (p Conclusion: The efficacy of triflusal in the secondary prevention of vascular events is similar to aspirin when administered for 12 months. Importantly, triflusal significantly reduced the incidence of ΜΙ and showed a better safety profile compared with aspirin. : (ASpirin versus Triflusal for Event Reduction In Atherothrombosis Secondary prevention, ASTERIAS trial; Clinical Trials.gov Identifier: NCT02616497).
- Published
- 2018
25. Simultaneous Dual Coronary Fistulas
- Author
-
Ioannis Ntalas, Júlia Karády, John C. Chambers, and Ronak Rajani
- Subjects
Male ,lcsh:Diseases of the circulatory (Cardiovascular) system ,Systolic Murmurs ,medicine.medical_specialty ,Computed Tomography Angiography ,Coronary Artery Disease ,Lesion ,Arterio-Arterial Fistula ,medicine.artery ,Internal medicine ,Ectasia ,Ascending aorta ,Humans ,Medicine ,Computed tomography angiography ,medicine.diagnostic_test ,business.industry ,Auscultation ,Middle Aged ,Echocardiography ,lcsh:RC666-701 ,Right coronary artery ,Image ,cardiovascular system ,Cardiology ,Parasternal long axis view ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business - Abstract
A 61-year-old man with type II diabetes mellitus was referred with breathlessness on exertion. On auscultation, there was a continuous ejection systolic murmur on the left upper sternal border. Transthoracic echocardiography showed a dilated vessel in aortic wall in the parasternal long axis view () and a spherical lesion in the apical 4-chamber view (). A coronary computed tomographic angiographic (CTCA) study revealed a dilated and ectatic right coronary artery (RCA). It arose from the ascending aorta at the 12 [...]
- Published
- 2018
26. Computational fluid dynamic modelling to determine the hemodynamic effects of implanting a transcatheter mitral valve within the left ventricle
- Author
-
Júlia Karády, Steven A. Niederer, Pál Maurovich-Horvat, Ronak Rajani, Adelaide de Vecchi, and Ioannis Ntalas
- Subjects
Male ,Patient-Specific Modeling ,Cardiac Catheterization ,medicine.medical_specialty ,Computed Tomography Angiography ,Heart Ventricles ,medicine.medical_treatment ,Hemodynamics ,030204 cardiovascular system & hematology ,Dynamic modelling ,Ventricular Outflow Obstruction ,03 medical and health sciences ,Imaging, Three-Dimensional ,0302 clinical medicine ,Internal medicine ,Mitral valve ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,030212 general & internal medicine ,Cardiac imaging ,Hemodynamic effects ,Cardiac catheterization ,Aged, 80 and over ,Heart Valve Prosthesis Implantation ,Prosthetic valve ,business.industry ,Endovascular Procedures ,Mitral Valve Insufficiency ,Aortic Valve Stenosis ,medicine.anatomical_structure ,Ventricle ,Heart Valve Prosthesis ,Hydrodynamics ,Cardiology ,Mitral Valve ,Cardiology and Cardiovascular Medicine ,business - Published
- 2017
27. Transcatheter mitral valve replacement in mitral annulus calcification - 'The art of computer simulation'
- Author
-
Júlia Karády, Ioannis Ntalas, Steven A. Niederer, Christopher Blauth, Pál Maurovich-Horvat, Ronak Rajani, and Bernard Prendergast
- Subjects
Male ,Patient-Specific Modeling ,medicine.medical_specialty ,Cardiac Catheterization ,Cardiac computed tomography ,medicine.medical_treatment ,Technical failure ,Ventricular outflow tract obstruction ,030204 cardiovascular system & hematology ,Severity of Illness Index ,Transcatheter Aortic Valve Replacement ,03 medical and health sciences ,0302 clinical medicine ,Predictive Value of Tests ,Internal medicine ,Mitral valve ,Multidetector Computed Tomography ,medicine ,Humans ,Mitral Valve Stenosis ,Radiology, Nuclear Medicine and imaging ,030212 general & internal medicine ,Simulation based ,Aged ,Prosthetic valve ,Aged, 80 and over ,Heart Valve Prosthesis Implantation ,business.industry ,Mitral valve replacement ,Models, Cardiovascular ,Calcinosis ,Mitral Valve Insufficiency ,Computer simulation ,medicine.anatomical_structure ,Treatment Outcome ,Heart Valve Prosthesis ,Cardiology ,Mitral Valve ,Radiographic Image Interpretation, Computer-Assisted ,Female ,medicine.symptom ,Mitral annulus calcification ,Cardiology and Cardiovascular Medicine ,business ,Transcatheter mitral valve replacement ,Finite element simulation - Abstract
There is considerable interest in transcatheter prosthetic valve treatment for mitral valve disease in high-risk individuals. Although the presence of mitral annular calcium (MAC) may provide an anchoring zone for such devices, results to date have been modest with reported technical failure rates approaching 30% in specialist centers. This in part relates to the risk of left ventricular outflow tract obstruction and device dislodgment but also to the lack of specific imaging guidelines to plan for such procedures. We present the use of finite element analysis and computer simulation based on cardiac CT in three patients with severe MAC in whom transcatheter devices were considered. In the first two cases, the computer simulations were performed after the clinical procedure and were concordant with the clinical outcome. For the third case, computer simulation was performed prior to the clinical procedure. This indicated unsuitability for transcatheter device deployment and a subsequent medical management was adopted. Overall, our initial results suggest that computer simulation may have the potential to improve patient selection for transcatheter mitral valve replacement in the presence of significant MAC.
- Published
- 2017
28. Remodelling of the aorta after a catheter-induced acute aortic dissection
- Author
-
Ioannis Ntalas, Amit Gupta, Athanasios Antoniou, and Rizwan Attia
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Cardiac Catheterization ,medicine.medical_treatment ,Iatrogenic Disease ,030204 cardiovascular system & hematology ,Cardiac Catheters ,03 medical and health sciences ,0302 clinical medicine ,Percutaneous Coronary Intervention ,medicine.artery ,Angioplasty ,Coronary stent ,medicine ,Humans ,Aortic dissection ,Aged, 80 and over ,Aorta ,Aortic Aneurysm, Thoracic ,business.industry ,Percutaneous coronary intervention ,General Medicine ,medicine.disease ,Surgery ,Dissection ,Catheter ,Aortic Dissection ,Right coronary artery ,Female ,Cardiology and Cardiovascular Medicine ,business ,030217 neurology & neurosurgery - Abstract
Iatrogenic acute aortic dissection during percutaneous coronary intervention is an extremely rare but critical complication. Although sealing the entry point with a coronary stent is an option to treat localized dissections, more extensive cases may require surgical intervention. We present a case of Type A aortic dissection that occurred during an angioplasty of a chronically occluded right coronary artery. Despite the extent of the dissection, a 'watch-and-wait' strategy was chosen, and repeated imaging a few days later revealed that the aorta had been remodelled to its normal anatomy.
- Published
- 2017
29. Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A report from the GReek AntiPlatelet rEgistry (GRAPE)
- Author
-
Dimitrios Alexopoulos, Ioannis Ntalas, Michalis Hamilos, Spyridon Deftereos, John A. Goudevenos, Stylianos Petousis, Manolis Vavuranakis, Ioannis Kanakakis, George Sitafidis, Christodoulos Stefanadis, Ioanna Xanthopoulou, Haralambos Parissis, Christos Angelidis, and George Hahalis
- Subjects
Male ,Ticagrelor ,medicine.medical_specialty ,Acute coronary syndrome ,Adenosine ,Ticlopidine ,Prasugrel ,medicine.medical_treatment ,Myocardial Infarction ,Administration, Oral ,Hemorrhage ,Thiophenes ,Piperazines ,Percutaneous Coronary Intervention ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Registries ,Acute Coronary Syndrome ,Practolol ,Aged ,business.industry ,Percutaneous coronary intervention ,Middle Aged ,medicine.disease ,Clopidogrel ,Combined Modality Therapy ,Receptors, Purinergic P2Y12 ,Surgery ,Clinical trial ,Conventional PCI ,Purinergic P2Y Receptor Antagonists ,Female ,Cardiology and Cardiovascular Medicine ,business ,Prasugrel Hydrochloride ,Platelet Aggregation Inhibitors ,Cohort study ,medicine.drug - Abstract
Background Few data exist about the implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Methods GReek AntiPlatelet rEgistry (GRAPE), initiated on January 2012, is a prospective, observational, multicenter cohort study focusing on contemporary use of P2Y12 inhibitors. In 1434 patients we evaluated appropriateness of P2Y12 selection initially and at discharge by applying an eligibility-assessing algorithm based on P2Y12 inhibitors' contraindications/specific warnings and precautions. Results Appropriate, less preferable and inappropriate P2Y12 inhibitor selections were made initially in 45.8%, 47.2% and 6.6% and at discharge in 64.1%, 29.2% and 6.6% of patients, respectively. The selection of clopidogrel was most commonly less preferable, both initially (69.7%) and at discharge (75.6%). Appropriate selection of newer agents was high initially (79.2%–82.8%), with further increase as selection at discharge (89.4%–89.8%). Inappropriate selection of the newer agents was 17.2%–20.8% initially, decreasing to 10.2%–10.6% at discharge. Conditions and co-medications related to increased bleeding risk, presentation with ST elevation myocardial infarction and the absence of reperfusion within the first 24h were the most powerful predictors of appropriate P2Y12 selection initially, whereas age ≥75years, conditions and co-medications related to increased bleeding risk and regional trends mostly affected appropriate P2Y12 selection at discharge. Conclusions In GRAPE, adherence with the recently released guidelines on oral antiplatelet therapy was satisfactory. Clopidogrel was most commonly used as a less preferable selection, while prasugrel or ticagrelor selection was mostly appropriate. Certain factors may predict initial and at discharge guideline implementation. Clinical Trial Registration -clinicaltrials.gov Identifier: NCT01774955 http://clinicaltrials.gov/.
- Published
- 2013
30. Antiplatelet Treatment in the Secondary Prevention of Coronary and Cerebrovascular Disease
- Author
-
Ioannis Ntalas, John A. Goudevenos, Kallirroi I Kalantzi, Haralampos J. Milionis, and Anastazia Kei
- Subjects
medicine.medical_specialty ,Aspirin ,Prasugrel ,business.industry ,Myocardial Infarction ,Disease ,Clopidogrel ,medicine.disease ,Stroke ,P2Y12 ,Fibrinolytic Agents ,Ischemic Attack, Transient ,Antithrombotic ,Secondary Prevention ,medicine ,Humans ,Drug Therapy, Combination ,Cardiology and Cardiovascular Medicine ,Intensive care medicine ,business ,Ticagrelor ,Platelet Aggregation Inhibitors ,Factor Xa Inhibitors ,medicine.drug - Abstract
Ischemic heart disease and cerebrovascular disease remain major health problems with associated mortality and quality-of-life consequences. Antiplatelet agents, including thienopyridines and the new P2Y12 inhibitors, have been shown to improve survival in the secondary prevention setting. We review the available evidence on the effectiveness and safety of previous established as well as novel antithrombotic agents in the secondary prevention of cardiovascular disease with a special focus on cerebrovascular disease.
- Published
- 2013
31. The Doppler paradox
- Author
-
Júlia Karády, Stam Kapetanakis, Ioannis Ntalas, and Ronak Rajani
- Subjects
medicine.medical_specialty ,genetic structures ,Echocardiography, Three-Dimensional ,Heart Valve Diseases ,Computed tomography ,Mechanical Mitral Valve ,medicine ,Humans ,Fluoroscopy ,Radiology, Nuclear Medicine and imaging ,PROGRESSIVE SYMPTOMS ,Prosthetic Valve Thrombosis ,Severe complication ,Prosthetic valve ,medicine.diagnostic_test ,Surrogate endpoint ,business.industry ,Coronary Thrombosis ,Middle Aged ,Echocardiography, Doppler ,Prosthesis Failure ,Heart Valve Prosthesis ,Mitral Valve ,Female ,Radiology ,Tomography, X-Ray Computed ,Cardiology and Cardiovascular Medicine ,business - Abstract
Obstructive prosthetic valve thrombosis (PVT) is a rare but severe complication that usually occurs in the presence of suboptimal anticoagulation. Although fluoroscopy is commonly used to detect abnormal leaflet motion as a surrogate marker for PVT, its inability to directly visualize adjacent tissue and valve physiology leaves it susceptible to miss clinically important PVT. In this manuscript, we report the case of a 54-year-old woman with a mechanical mitral valve who was admitted to our institute with exertional dyspnea. Although valve fluoroscopy was normal, subsequent 3D echocardiography and ECG-gated multiphase computed tomography confirmed the presence of PVT that was subsequently treated successfully with surgical replacement. Our case demonstrates the utility of multimodality imaging in establishing PVT in patients with abnormal prosthetic valve physiology and progressive symptoms.
- Published
- 2017
32. Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate
- Author
-
Kallirroi I Kalantzi, Ioannis Goudevenos, Andromachi A Dimitriou, Alexandros D. Tselepis, Ioannis Ntalas, and Maria E. Tsoumani
- Subjects
Male ,medicine.medical_specialty ,Acute coronary syndrome ,Ticlopidine ,Platelet Aggregation ,medicine.medical_treatment ,Loading dose ,law.invention ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,In patient ,Platelet ,cardiovascular diseases ,Acute Coronary Syndrome ,Aged ,Pharmacology ,business.industry ,Percutaneous coronary intervention ,General Medicine ,Middle Aged ,medicine.disease ,Clopidogrel ,Conventional PCI ,Purinergic P2Y Receptor Antagonists ,Cardiology ,Female ,business ,Platelet Aggregation Inhibitors ,circulatory and respiratory physiology ,medicine.drug - Abstract
The efficacy of clopidogrel therapy in patients with an acute coronary syndrome (ACS) has been established using the clopidogrel hydrogen sulfate (CHS) formulation. In this study we compared the antiplatelet effectiveness of a generic clopidogrel salt, clopidogrel besylate (CB), with the original CHS in patients with an ACS.Ninety-six ACS patients were randomized to receive a 600-mg loading dose of either CHS (n = 45) or CB (n = 51), followed by 75 mg/day. Sixty-eight patients underwent a percutaneous coronary intervention (PCI), whereas 28 were treated conservatively. Platelet aggregatory response, vasodilator-stimulated phosphoprotein (VASP) phosphorylation, P-selectin expression and platelet-leucocyte conjugates were determined before clopidogrel loading (baseline), as well as at 5 days and at 1 month afterwards.No difference in the clopidogrel response variability was observed between patients receiving CHS or CB either at 5 days or at 1 month of follow-up. Similarly, no difference in the inhibition of platelet aggregation, P-selectin expression or in the platelet-leucocyte conjugates was observed between CHS and CB group during the follow-up.There is no overall significant difference in the antiplatelet efficacy between CB and CHS during their administration in ACS patients for up to 1 month after the episode.
- Published
- 2011
33. Antiplatelet Efficacy of Long-Term Treatment With Clopidogrel Besylate in Patients With a History of Acute Coronary Syndrome
- Author
-
Ioannis Goudevenos, Maria E. Tsoumani, Kallirroi I Kalantzi, Andromachi A Dimitriou, Alexandros D. Tselepis, and Ioannis Ntalas
- Subjects
Clopidogrel besylate ,Acute coronary syndrome ,medicine.medical_specialty ,Ticlopidine ,Randomization ,Platelet Aggregation ,Gastroenterology ,law.invention ,Randomized controlled trial ,law ,Internal medicine ,Drugs, Generic ,Humans ,Medicine ,Platelet ,In patient ,cardiovascular diseases ,Acute Coronary Syndrome ,skin and connective tissue diseases ,integumentary system ,business.industry ,medicine.disease ,Clopidogrel ,Long-Term Care ,Treatment Outcome ,Clopidogrel hydrogen sulfate ,Anesthesia ,Cardiology and Cardiovascular Medicine ,business ,Platelet Aggregation Inhibitors ,medicine.drug - Abstract
The efficacy of clopidogrel therapy in patients with an acute coronary syndrome (ACS) has been established using the clopidogrel hydrogen sulfate (CHS) formulation. We compared the antiplatelet effectiveness of long-term administration of the original CHS with a generic clopidogrel besylate (CB) salt formulation in 86 patients with a history of an ACS. At 1 month after the episode, patients receiving 75 mg/d CHS were randomized to continue with CHS (n = 41) or to switch to 75 mg/d CB (n = 45). Platelet aggregation, vasodilator-stimulated phosphoprotein (VASP) phosphorylation, P-selectin expression, and platelet–leucocyte conjugates were determined before randomization and at 6 months afterward. No difference in any platelet parameter studied was observed between the 2 groups either before randomization or after 6 months of treatment with CHS or CB. We conclude that there is no difference in the antiplatelet efficacy between CB and CHS during long-term administration in patients with a history of an ACS.
- Published
- 2011
34. Saccharomyces boulardiiandCandida albicansexperimental colonization of the murine gut
- Author
-
George Samonis, Ioannis Ntalas, Diamantis P. Kofteridis, Sofia Maraki, Markos Ntaoukakis, Matthew E. Falagas, and S. Lionakis
- Subjects
Male ,Administration, Oral ,law.invention ,Microbiology ,Feces ,Mice ,Saccharomyces ,Probiotic ,law ,Oral administration ,Candida albicans ,medicine ,Animals ,Colonization ,Fungemia ,Mice, Inbred ICR ,Gastrointestinal tract ,biology ,Probiotics ,Candidiasis ,General Medicine ,biology.organism_classification ,medicine.disease ,Corpus albicans ,Gastrointestinal Tract ,Infectious Diseases ,Models, Animal ,Saccharomyces boulardii - Abstract
Saccharomyces boulardii has been and continues to be extensively used as a probiotic, with only rare associations with fungemia. This study evaluated the virulence of this yeast when given as a probiotic, and its role in preventing gastrointestinal (GI) colonization by Candida . Adult male Crl:CD1 (ICR) BR mice were given S. boulardii orally in three different doses or normal saline for 14 days. Stool cultures were performed at the time of discontinuation of yeast administration, as well as 1 and 2 weeks later. Gut colonization was proportional to the given dose but lasted only 1 week and no dissemination of the yeast was detected. S. boulardii was also given for 2 and 4 weeks to mice fed chow containing Candida albicans . S. boulardii in the gut did not affect Candida GI colonization. These fi ndings suggest that oral administration of S. boulardii induces a substantial but short term increase of this yeast in the intestinal lumen and administration of the probiotic does not prevent subsequent GI colonization by C. albicans .
- Published
- 2011
35. P418Contemporary diagnostic yield of implantable loop recorders in patients from Northwestern Greece in the setting of economic crisis
- Author
-
A Bechlioulis, Dimitrios Nikas, Panagiotis Korantzopoulos, Ioannis Goudevenos, and Ioannis Ntalas
- Subjects
Loop (topology) ,Control theory ,business.industry ,Physiology (medical) ,Yield (finance) ,Medicine ,In patient ,Cardiology and Cardiovascular Medicine ,business - Published
- 2018
36. Evaluating the bioequivalence of clopidogrel generic formulations
- Author
-
Maria E. Tsoumani, Ioannis Ntalas, A.D. Tselepis, and John A. Goudevenos
- Subjects
Ticlopidine ,Therapeutic equivalency ,business.industry ,Chemistry, Pharmaceutical ,MEDLINE ,Drugs generic ,General Medicine ,Bioequivalence ,Pharmacology ,Clopidogrel ,Therapeutic Equivalency ,medicine ,Platelet aggregation inhibitor ,Drugs, Generic ,Humans ,business ,Platelet Aggregation Inhibitors ,medicine.drug - Published
- 2015
37. Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial
- Author
-
Maria Thoma, Maria Voukelatou, Leonidas Peltekis, Georgios Goumas, Spiros Konstantinou, Demosthenes B. Panagiotakos, Christos Charmpas, Haralampos J. Milionis, Konstantinos Vemmos, Adamantios Bourdakis, John A. Goudevenos, Christos S. Stroumbis, Konstantinos Vardakis, Ioannis Sinteles, Zacharias Christogiannis, Antonios Draganigos, Alexandros D. Tselepis, Georgios Giannakoulas, Maria E. Tsoumani, Nikos Dimoulis, Kyriafina Terzoudi, Ioannis Efthimiadis, Ioannis Ntalas, Karmelos Tsilias, Ioannis Xaraktsis, Vasileios Giogiakas, Nikolaos Kipouridis, Georgios Hatziathanasiou, Evangelos Kazakos, Nikos Prokopakis, Dimitrios Nikolopoulos, John N. Vakalis, Ioannis Giatrakos, Kalliroi I. Kalantzi, and Vasileios Vasilakopoulos
- Subjects
Clopidogrel besylate ,Male ,medicine.medical_specialty ,Ticlopidine ,Myocardial Infarction ,Hemorrhage ,Internal medicine ,medicine ,Secondary Prevention ,Drugs, Generic ,Humans ,Myocardial infarction ,Stroke ,Aged ,Pharmacology ,Secondary prevention ,Aged, 80 and over ,business.industry ,Thrombosis ,Middle Aged ,medicine.disease ,Clopidogrel ,Interim analysis ,Surgery ,Clinical trial ,Treatment Outcome ,Female ,Cardiology and Cardiovascular Medicine ,business ,Platelet Aggregation Inhibitors ,medicine.drug ,Month follow up ,Follow-Up Studies - Abstract
Background: The aim of the present interim analysis was to compare the clinical efficacy and safety of the generic clopidogrel besylate (CB) with the innovator clopidogrel hydrogen sulphate (CHS) salt in patient groups eligible to receive clopidogrel. Methods: A 2-arm, multicenter, open-label, phase 4 clinical trial. Consecutive patients (n=1,864) were screened and 1,800 were enrolled in the trial and randomized to CHS (n=759) or CB (n=798). Primary efficacy end point was the composite of myocardial infarction, stroke or death from vascular causes, and primary safety end point was rate of bleeding events as defined by Bleeding Academic Research Consortium (BARC) criteria. Results: At 6-months follow-up no differences were observed between CB and CHS in primary efficacy end point (OR, 0.80; 95% CI, 0.37 to 1.71; p=0.57). Rates of BARC-1,-2,-3a and -5b bleeding were similar between the two study groups whereas no bleeding events according to BARC-3b, -3c, -4 and -5a were observed in either CHS or CB group. Conclusion: The clinical efficacy and safety of the generic CB is similar to that of the innovator CHS salt, thus, it can be routinely used in the secondary prevention of atherothrombotic events for a period of at least 6 months. (Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence, SCIENCE study Clinical Trials.gov Identifier: NCT02126982).
- Published
- 2015
38. Atrial Fibrillation in Athletes
- Author
-
Ioannis Ntalas, Dimitrios G. Ketikoglou, and Christos A. Goudis
- Subjects
medicine.medical_specialty ,Electric Countershock ,Myocardial Ischemia ,Management of atrial fibrillation ,Angiotensin-Converting Enzyme Inhibitors ,macromolecular substances ,Systemic inflammation ,Autonomic Nervous System ,Angiotensin Receptor Antagonists ,Quality of life ,Internal medicine ,Thromboembolism ,Epidemiology ,Atrial Fibrillation ,medicine ,Prevalence ,Humans ,cardiovascular diseases ,Atrial ectopic beats ,Exercise ,Inflammation ,biology ,business.industry ,Athletes ,Anticoagulants ,Atrial fibrillation ,General Medicine ,Atrial Remodeling ,medicine.disease ,biology.organism_classification ,cardiovascular system ,Cardiology ,Catheter Ablation ,Atrial Premature Complexes ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Platelet Aggregation Inhibitors - Abstract
Atrial fibrillation is the most common arrhythmia in athletes and may be associated with endurance sport practice. Atrial ectopic beats, chronic systemic inflammation, autonomic system alterations, anatomic adaptation, myocardial injury and illicit drugs seem to be implicated in the increased prevalence of atrial fibrillation in athletes, but clear evidence is lacking. Treatment of the arrhythmia is a challenging issue, as atrial fibrillation may impair athletic performances and deteriorate athletes' quality of life. This review focuses on the epidemiology, possible pathophysiological mechanisms, and management of atrial fibrillation in athletes.
- Published
- 2014
39. Diabetes mellitus and atrial fibrillation: Pathophysiological mechanisms and potential upstream therapies
- Author
-
Eleftherios M. Kallergis, Christos A. Goudis, Dimitrios G. Ketikoglou, Panagiotis Korantzopoulos, Tong Liu, and Ioannis Ntalas
- Subjects
medicine.medical_specialty ,Ventricular Remodeling ,business.industry ,Anti-Inflammatory Agents ,Atrial fibrillation ,Structural remodeling ,medicine.disease ,Pathophysiology ,Antioxidants ,Oxidative Stress ,Risk Factors ,Internal medicine ,Diabetes mellitus ,Atrial Fibrillation ,medicine ,Cardiology ,Diabetes Mellitus ,Animals ,Humans ,Cardiology and Cardiovascular Medicine ,business ,Ventricular remodeling ,Atrial Remodeling ,Glycemic - Abstract
Diabetes mellitus (DM) represents one of the most important risk factors for atrial fibrillation (AF) while AF is a strong and independent marker of overall mortality and cardiovascular morbidity in diabetic patients. Autonomic, electrical, electromechanical, and structural remodeling, including oxidative stress, connexin remodeling and glycemic fluctuations seem to be implicated in AF pathophysiology in the setting of DM. The present review highlights the association between DM and AF, provides a comprehensive overview of the responsible pathophysiological mechanisms and briefly discusses potential upstream therapies for DM-related atrial remodeling.
- Published
- 2014
40. Contraindications/special warnings and precautions for use of contemporary oral antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention
- Author
-
Dimitrios, Alexopoulos, Ioanna, Xanthopoulou, Spyridon, Deftereos, George, Sitafidis, Ioannis, Kanakakis, Michalis, Hamilos, Manolis, Vavuranakis, Periklis, Davlouros, Ioannis, Ntalas, Christos, Angelidis, George, Hahalis, Filippos, Triposkiadis, Panos, Vardas, Christodoulos, Stefanadis, and John A, Goudevenos
- Subjects
Male ,Percutaneous Coronary Intervention ,Age Factors ,Administration, Oral ,Humans ,Female ,Hemorrhage ,Registries ,Acute Coronary Syndrome ,Middle Aged ,Platelet Aggregation Inhibitors ,Receptors, Purinergic P2Y12 ,Aged - Abstract
The prevalence of contraindications/special warnings and precautions (CON/SWP) for clopidogrel, prasugrel and ticagrelor use is not adequately studied and might affect P2Y12 inhibitor choice in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI).In the context of the GReek AntiPlatelet rEgistry (GRAPE) a detailed recording of CON/SWP for use of clopidogrel, prasugrel and ticagrelor was done for 1,280 consecutive, moderate-high-risk ACS patients undergoing PCI. At least 1 CON for use of clopidogrel, prasugrel and ticagrelor was present in 5 (0.4%), 49 (3.8%) and 12 patients (0.9%), respectively. Prevalence of at least 1 CON/SWP to clopidogrel (45.8%) was less frequent compared to prasugrel (49.1%) or ticagrelor (49.1%; P=0.02 and P=0.04, respectively), while 34% of patients had at least 1 CON/SWP to all the 3 P2Y12 inhibitors. At discharge, 482 (38.6%), 301 (24.1%) and 464 patients (37.2%) received clopidogrel, prasugrel and ticagrelor, respectively. Age ≥75 years, co-medication related to increased bleeding risk, and history of asthma/chronic obstructive pulmonary disease favored clopidogrel vs. prasugrel or ticagrelor use as discharge medication, while geographic region also affected this choice (C-statistic, 0.81; 95% CI: 0.78-0.83).In patients with ACS undergoing PCI the prevalence of CON to antiplatelet agents is low, whereas that of SWP is high. Certain SWP, along with regional trends may affect the choice of newer P2Y12 inhibitors vs. clopidogrel.
- Published
- 2013
41. Munchausen syndrome presented as recurrent syncope
- Author
-
Panagiotis Korantzopoulos, Ioannis Ntalas, John A. Goudevenos, and Ilias Massis
- Subjects
Pediatrics ,medicine.medical_specialty ,biology ,business.industry ,medicine ,Implantable loop recorder ,Syncope (genus) ,Munchausen syndrome ,Cardiology and Cardiovascular Medicine ,medicine.disease ,business ,biology.organism_classification - Published
- 2015
42. IN-HOSPITAL SWITCHING OF P2Y12 INHIBITOR IN REAL-LIFE PATIENTS WITH ACUTE CORONARY SYNDROME: INSIGHTS FROM THE GREEK ANTIPLATELET (GRAPE) REGISTRY
- Author
-
Dimitrios Alexopoulos, Ioannis Ntalas, Vlassis Pyrgakis, Spyridon Deftereos, Periklis Davlouros, Filippos Triposkiadis, Evropi Tsoni, Ioanna Xanthopoulou, George Sitafidis, and Ioannis Goudevenos
- Subjects
Acute coronary syndrome ,medicine.medical_specialty ,P2Y12 ,business.industry ,Emergency medicine ,medicine ,In real life ,medicine.disease ,business ,Cardiology and Cardiovascular Medicine - Published
- 2013
- Full Text
- View/download PDF
43. The increased activation state of resting platelets and the TRAP-induced platelet aggregation are related to platelet response variability to clopidogrel in acute coronary syndrome patients
- Author
-
Kallirroi I Kalantzi, Ioannis Ntalas, Maria E. Tsoumani, John A. Goudevenos, and A.D. Tselepis
- Subjects
medicine.medical_specialty ,Acute coronary syndrome ,business.industry ,Clopidogrel ,medicine.disease ,Response Variability ,Trap (computing) ,Internal medicine ,Induced platelet aggregation ,medicine ,Cardiology ,Platelet ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Published
- 2015
44. The assessment of genetic polymorphisms and their potential association with aspirin resistance in a population of Greek patients with acute coronary syndrome
- Author
-
Ketty Soteriadou, Ioannis Ntalas, Despina Smirlis, Antonia Efstathiou, Evi Gouzelou, A.D. Tselepis, Maria E. Tsoumani, and I.A. Goudevenos
- Subjects
medicine.medical_specialty ,education.field_of_study ,Acute coronary syndrome ,business.industry ,Internal medicine ,Population ,Physical therapy ,Medicine ,Cardiology and Cardiovascular Medicine ,business ,education ,medicine.disease ,ASPIRIN RESISTANCE - Published
- 2015
45. Use of ticagrelor in patients with ST-elevation myocardial infarction undergoing thrombolysis
- Author
-
Ioannis Ntalas, John A. Goudevenos, Kallirroi Kalantzi, Athanasios Pipilis, Dimitrios Alexopoulos, and Ioanna Xanthopoulou
- Subjects
medicine.medical_specialty ,Hematology ,business.industry ,medicine.medical_treatment ,Thrombolysis ,St elevation myocardial infarction ,Internal medicine ,medicine ,Cardiology ,In patient ,Cardiology and Cardiovascular Medicine ,business ,Ticagrelor ,medicine.drug - Published
- 2013
46. In-hospital bleeding in the era of newer P2Y12 inhibitors in real-life patients with acute coronary syndrome: results from the GReek AntiPlatElet (GRAPE) registry
- Author
-
Michalis Hamilos, E. Vavuranakis, Ioanna Xanthopoulou, George Sitafidis, Ioannis Ntalas, S. Loisos, Spyridon Deftereos, N. Vlassopoulou, Dimitrios Alexopoulos, and Dimitrios Stakos
- Subjects
medicine.medical_specialty ,Acute coronary syndrome ,education.field_of_study ,Gastrointestinal bleeding ,Prasugrel ,business.industry ,medicine.medical_treatment ,Population ,Percutaneous coronary intervention ,Context (language use) ,Clopidogrel ,medicine.disease ,Surgery ,Internal medicine ,Medicine ,Cardiology and Cardiovascular Medicine ,business ,education ,Ticagrelor ,medicine.drug - Abstract
Purpose: Data on in-hospital bleeding events with the concurrent use of clopidogrel, prasugrel and ticagrelor in real-life practice are lacking. Methods: In the context of GReek AntiPlatelet rEgistry (GRAPE), a prospective, observational, multicenter cohort study conducted in in 8 PCI-capable hospitals in Greece, we investigated in-hospital bleeding events (Bleeding Academic Research Consortium -BARC classification) in ACS patients undergoing percutaneous coronary intervention (PCI). Results: Between January and December 2012, 1280 patients were included in analysis (82.8% men, 22.7% diabetics, 53.5% admitted with ST elevation myocardial infarction (STEMI), with a mean age of 61.8±12.4 years). Overall, in-hospital bleeding BARC type 1, 2 3a and 3b occurred in 54 (4.2%), 31 (2.4%), 21 (1.6%) and 5 (0.4%) patients respectively. No fatal bleeding event occurred. In the subgroup of patients who were initially treated either with clopidogrel (N=478), prasugrel (N=92) or ticagrelor (N=228) without switching thereafter, multivariate analysis (backward logistic regression) revealed age≥75 years and recent/recurrent gastrointestinal (GI) bleeding as predictive factors of in-hospital bleeding BARC of any type (OR=2.14, 1.21-3.80 95% CIs, p=0.009 and OR=6.48, 1.13-37.2 95% CIs, p=0.04 respectively). In 215 propensity-matched pairs of patients, rate of in-hospital bleeding BARC of any type did not differ significantly between clopidogrel vs prasugrel or ticagrelor -treated patients (3.7% vs 7.9%, p=0.098). Conclusions: In a real-world PCI-treated ACS population, older age and previous GI bleeding are associated with an increased risk of low to moderate severity in-hospital bleeding events. A trend towards more bleeding with the newer agents is apparent.
- Published
- 2013
47. Switching of P2Y12 inhibitor in patients with acute coronary syndrome: Insights from the GReek AntiPlatElet Registry (GRAPE)
- Author
-
C. Angelidis, Dimitrios Alexopoulos, A. Siapika, Ioannis Ntalas, H. Parissis, K. Stavrou, A. Perperis, Ioanna Xanthopoulou, and S. Petousis
- Subjects
Acute coronary syndrome ,medicine.medical_specialty ,Prasugrel ,business.industry ,medicine.medical_treatment ,Percutaneous coronary intervention ,medicine.disease ,Clopidogrel ,P2Y12 ,Internal medicine ,Diabetes mellitus ,medicine ,Cardiology ,In patient ,Cardiology and Cardiovascular Medicine ,business ,Ticagrelor ,medicine.drug - Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.